RECEIVED
CENTRAL FAX CENTER

FEB 2 6 2007

FAX TRANSMISSION

DATE: February 26, 2007

PTO IDENTIFIER: **Application Number**   10/010,942-Conf. #5594
                      Patent Number
Inventor: Guriq BASI et al.

MESSAGE TO: US Patent and Trademark Office
FAX NUMBER: (571) 273-8300

FROM: LAHIVE & COCKFIELD, LLP

Amy E. Mandragouras, Esq.

PHONE: (617) 227-7400

Attorney Dkt. #:   ELN-002

PAGES (Including Cover Sheet):   114

CONTENTS:
Fee Transmittal (1 page)
Transmittal (1 page)
Petition for Reconsideration Under 37 CFR 1.705(b) and/or 1.705(c)
Exhibits 1-17
Certificate of Transmission (1 page)

If your receipt of this transmission is in error, please notify this firm immediately by collect call to sender at (617) 227-7400 and send the original transmission to us by return mail at the address below.

This transmission is intended for the sole use of the individual and entity to whom it is addressed, and may contain information that is privileged, confidential and exempt from disclosure under applicable law. You are hereby notified that any dissemination, distribution or duplication of this transmission by someone other than the intended addressee or its designated agent is strictly prohibited.

LAHIVE & COCKFIELD, LLP
One Post Office Square, Boston, Massachusetts 02109-2127
Telephone: (617) 227-7400   Facsimile: (617) 742-4214

1

RECEIVED
CENTRAL FAX CENTER

FEB 2 6 2007

PTO/SB/97 (09-04)
Approved for use through 07/31/2008 OMB 0651-0031
U S Patent and Trademark Office. U S DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Application No (if known) 10/010,942

Attorney Docket No.: ELN-002

Certificate of Transmission under 37 CFR 1.8

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office

on _____February 26, 2007_____ .
                Date

_____
                Signature

Amy E. Mandragouras, Esq.
Typed or printed name of person signing Certificate

        36,207   (617) 227-7400
Registration Number, if applicable   Telephone Number

Note: Each paper must have its own certificate of transmission, or this certificate must
        identify each submitted paper

        Fee Transmittal (1 page)
        Transmittal (1 page)
        Petition for Reconsideration Under 37 CFR 1.705(b) and/or 1.705(c)
   Exhibits 1-17

2

RECEIVED
CENTRAL FAX CENTER

FEB 2 6 2007

PTO/SB/21 (09-06)
Approved for use through 03/31/2007 OMB 0651-0031
U.S Patent and Trademark Office, U S DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	10/010,942-Conf #5594
Filing Date	December 6, 2001
First Named Inventor	Guriq BASI
Art Unit	1649
Examiner Name	K. A. Ballard
Attorney Docket Number	ELN-002

Total Number of Pages in This Submission

ENCLOSURES (Check all that apply)

[x] Fee Transmittal Form

[ ] Fee Attached

[ ] Amendment/Reply

[ ] After Final

[ ] Affidavits/declaration(s)

[ ] Extension of Time Request

[ ] Express Abandonment Request

[ ] Information Disclosure Statement

[ ] Certified Copy of Priority Document(s)

[ ] Reply to Missing Parts/ Incomplete Application

[ ] Reply to Missing Parts under 37 CFR 1 52 or 1 53

[ ] Drawing(s)

[ ] Licensing-related Papers

[ ] Petition

[ ] Petition to Convert to a Provisional Application

[ ] Power of Attorney, Revocation Change of Correspondence Address

[ ] Terminal Disclaimer

[ ] Request for Refund

[ ] CD, Number of CD(s) _____

[ ] Landscape Table on CD

Remarks

[ ] After Allowance Communication to TC

[ ] Appeal Communication to Board of Appeals and Interferences

[ ] Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)

[ ] Proprietary Information

[ ] Status Letter

[x] Other Enclosure(s) (please identify below):

Petition for Reconsideration Under 37 CFR 1.705(b) and/or 1.705(c):
Exhibits 1-17:
Certificate of Transmission under 37 CFR1.8

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	LAHIVE & COCKFIELD, LLP
Signature	
Printed name	Amy E Mandragouras, Esq
Date	February 26, 2007

Reg No 36,207

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted by facsimile to the Patent and Trademark Office, facsimile no (571) 273-8300 a Commissioner for Patents, P O Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Dated February 26, 2007

Signature _____ (Amy E Mandragouras, Esq)

RECEIVED
CENTRAL FAX CENTER

FEB 2 6 2007

PTO/SB/17 (07-06)
Approved for use through 01/31/2007. OMB 0651-0032
U.S. Patent and Trademark Office. U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no person are required to respond to a collection of information unless it displays a valid OMB control number

	Complete if Known	
Effective on 12/08/2004 Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818)	Application Number	10/010,942-Conf. #5594
FEE TRANSMITTAL	Filing Date	December 6, 2001
For FY 2006	First Named Inventor	Gunq BASI
	Examiner Name	K. A. Ballard
☐ Applicant claims small entity status See 37 CFR 1.27	Art Unit	1649
TOTAL AMOUNT OF PAYMENT ($) 0.00	Attorney Docket No	ELN-002

METHOD OF PAYMENT (check all that apply)

☐ Check   ☐ Credit Card   ☐ Money Order   ☐ None   ☐ Other (please identify): _____

☒ Deposit Account   Deposit Account Number 12-0080   Deposit Account Name Lahive & Cockfield, LLP

For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)

☒ Charge fee(s) indicated below

☒ Charge any additional fee(s) or underpayments of fee(s) under 37 CFR 1.16 and 1.17

☐ Charge fee(s) indicated below, except for the filing fee

☒ Credit any overpayments

FEE CALCULATION

1. BASIC FILING, SEARCH, AND EXAMINATION FEES

Application Type	FILING FEES Fee ($)	Small Entity Fee ($)	SEARCH FEES Fee ($)	Small Entity Fee ($)	EXAMINATION FEES Fee ($)	Small Entity Fee ($)	Fees Paid ($)
Utility	300	150	500	250	200	100	
Design	200	100	100	50	130	65	
Plant	200	100	300	150	160	80	
Reissue	300	150	500	250	600	300	
Provisional	200	100	0	0	0	0	

2. EXCESS CLAIM FEES

Fee Description	Fee ($)	Small Entity Fee ($)
Each claim over 20 (including Reissues)	50	25
Each independent claim over 3 (including Reissues)	200	100
Multiple dependent claims	360	180

Total Claims	Extra Claims	Fee ($)		Fee Paid ($)
_____ - 20 =		x	=	

HP = highest number of total claims paid for, if greater than 20.

Indep. Claims	Extra Claims	Fee ($)		Fee Paid ($)
_____ - 3 =		x	=	

HP = highest number of independent claims paid for, if greater than 3

Multiple Dependent Claims

Fee ($)	Fee Paid ($)

3. APPLICATION SIZE FEE

If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is $250 ($125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s)

Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof	Fee ($)	Fee Paid ($)
_____ - 100 =	/50	(round up to a whole number) x	-	

4. OTHER FEE(S)

Non-English Specification, $130 fee (no small entity discount)

Other (e.g., late filing surcharge). Petition for Reconsideration Under 37 CFR 1.705(b)   400.00

Petition for Reconsideration Under 37 CFR 1.705(c)   200.00

Fees Paid ($)

SUBMITTED BY		Registration No (Attorney/Agent)	36,207	Telephone	(617) 227-7400
Signature					
Name (Print/Type) Amy E. Mandragouras, Esq.				Date	February 26, 2007

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted by facsimile to the Patent and Trademark Office, facsimile no. (571) 273-8300 at Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below

Dated: February 26, 2007

Signature   (Amy E. Mandragouras, Esq.)

Docket No.: ELN-002
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
CENTRAL FAX CENTER

FEB 26 2007

In re Patent Application of:
Guriq Basi *et al.*

Application No : 10/010942

Filed: December 6, 2001

For: HUMANIZED ANTIBODIES THAT
RECOGNIZE BETA AMYLOID PEPTIDE

Confirmation No.: 5594

Art Unit: 1649

Examiner: Ballard, Kimberly A.

MS Petition
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REQUEST FOR RECONSIDERATION OF AN APPLICATION FOR PATENT TERM ADJUSTMENT PURSUANT TO 37 C.F.R. §1.705(b) AND/OR §1.705(c)

Dear Sir:

Pursuant to 37 C.F.R. §1.705(b) and/or §1.705(c), Applicants hereby petition for
reconsideration of the Application for Patent Term Adjustment filed on August 10, 2006
(hereinafter, "the Application") for the above-referenced patent application. This petition is
timely filed within two months of the date of Decision on Application for Patent Term
Adjustment dated December 26, 2006 (hereinafter "the Decision"). A copy of the Decision and
the Application are filed with this petition as Exhibits 1 and 2.

In the Decision the Petitions Examiner denied Applicants' request for correction of the
period of reduction of 107 days for Applicant delay under 37 C.F.R. § 1.704(b) and entry of a
new period of Applicant delay of 38 days in connection with Applicants' response to the Notice
to File Missing Parts mailed March 1, 2002 (*See* Decision on Petition, page 1, paragraph 4 to
page 2, paragraph 4). The Examiner's denial of the request was on the grounds that Applicants'
response to the Notice to File Missing Parts filed by Certificate of Mailing on July 1, 2002 (and
date stamped on July 8, 2002) allegedly contained an omission and that the period of 69 days

-1-

Serial No. 10/010,942

ELN-002

(beginning July 9, 2002 and ending September 16, 2002 with the filing of a paper correcting the omission) constituted a "failure to engage" pursuant to 37 C.F.R. § 1.704(c)(7).

As indicated by the Notice to Comply with Requirements for Patent Application Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures" mailed August 21, 2002, the alleged omission in this case is that Applicants' response of July 1, 2002 was missing a compliant sequence disk. The Notice indicates that the computer diskette was found to be "damaged and/or unreadable." (see Exhibit 3)

Applicants respectfully request reconsideration of the Application for Patent Term Adjustment on the grounds that Applicants' response did not in fact contain an "omission" on the part of the Applicants and, further, that the period of 69 days is not a "failure to engage" by Applicants. In particular, Applicants respectfully submit that Applicants filed a fully compliant response, including a fully compliant sequence disk on July 1, 2002. The fact that the disk was subsequently found to be damaged by the USPTO was not due to any lack of due care by Applicants, but instead due to the subsequent handling and treatment of the disk by others. Based on information provided by personnel at the USPTO following inspection of the USPTO file copy of the sequence disk filed on July 1, 2002, it is Applicants' understanding that the sequence disk is visibly damaged in a manner consistent with damage caused by irradiation treatment of the disk by the United States Postal Service. As such, Applicants' reply did not have an omission and the period of adjustment set forth in §1.703 should not have been reduced by 69 days (the number of days beginning on the day after the date of the reply having the alleged omission (i.e., July 9, 2002) and ending on the date a reply correcting the omission was filed (i.e., September 16, 2002)). Evidence in support of Applicants request for reconsideration is set forth below.

I.   Applicants' reply did not contain an omission as the sequence diskette of July 1, 2002 was fully compliant.

In support of their request for reconsideration, Applicants submit herewith copies of the following documents as evidence that Applicants' reply of July 1, 2002 did not contain an

-2-

Serial No. 10/010,942   ELN-002

omission and that the sequence disk was compliant and any damage was due to the subsequent handling and treatment by others:

(1)   A true copy of the return postcard dated July 1, 2002, originally filed with the above-referenced sequence disk describing the papers that constituted the filing package and indicating that a "Diskette containing the computer readable form of the Sequence Listing" was enclosed with a Certificate of First Class Mailing and indicating USPTO date-stamp of July 8, 2002 (see Exhibit 4; 1 page);

(2)   A true copy of Applicants' Attorney's file copy of the diskette label affixed to an envelope containing the sequence disk mailed July 1, 2002 and indicating that the sequence disk is dated July 1, 2002 (Exhibit 5);

(3)   A true paper copy of a sequence listing generated from Applicants' Attorney's file copy the sequence diskette mailed on July 1, 2002 (Exhibit 6);

(4)   A Verification Summary Report generated by the USPTO's "Checker" software program confirming that there are no sequence errors in Applicants' Attorney's file copy of the July 1, 2002 sequence listing (Exhibit 7);

(5)   An Affidavit executed by Ms. Micaela Hill affirming that Applicants' Attorney's file copy of the sequence diskette mailed July 1, 2002 is computer-readable and that the paper copy submitted as Exhibit 6 was generated from Applicants' Attorney's file copy of said sequence diskette (Exhibit 8);

(6)   A true paper copy of a sequence listing generated from Assignees' file copy of the sequence diskette mailed on July 1, 2002 (Exhibit 9);

(7)   An Affidavit executed by Ms. Patricia Robinson affirming that Assignees' file copy of the sequence diskette mailed July 1, 2002 is computer-readable and that the paper copy submitted as Exhibit 9 was generated from Assignees' file copy of said sequence diskette (Exhibit 10);

(8)   An Affidavit executed by Debra J. Milasincic, Esq. describing Applicants' Attorney's regular practice in connection with the preparation of sequence listings and sequence diskettes (Exhibit 11); .

-3-

Serial No. 10/010,942   ELN-002

(9)   A true copy of the return postcard dated September 16, 2002, filed in response to the Notice to Comply and describing the papers that constituted the filing package and indicating that a "Diskette containing the computer readable form of the Sequence Listing" was enclosed with a Certificate of First Class Mailing and indicating USPTO date-stamp of September 20, 2002 (see Exhibit 12);

(10)   A true copy of Applicants' Attorney's copy of the sequence diskette and envelope filed September 16, 2002 and indicating that the sequence disk is dated September 16, 2002 (Exhibit 13);

(11)   A true paper copy of Applicants' sequence listing filed September 19, 2002 which was found to be compliant (Exhibit 14);

(12)   A Statement from Applicants' Attorney confirming that Applicants' Attorney's paper copy of sequence listing filed July 1, 2002 (Exhibit 6) is **identical** to Applicants' Attorney's paper of the sequence listing filed September 19, 2002 (Exhibit 15).

Therefore, the fact that the sequence disks mailed July 1, 2002 and September 19, 2002 are identical and that the September 19, 2002 diskette was found to be compliant, is evidence that Applicants' diskette mailed July 1, 2002 was also compliant and that Applicants' Attorney used due care. Accordingly, Applicants respectfully submit that Applicants' reply of July 1, 2002 did not contain an omission in that the sequence disk mailed July 1, 2002 was fully compliant, but subsequently damaged by the handling and treatment of others.

II.   The sequence disk filed July 1, 2002 was damaged by the handling and treatment by the United Stated Postal Service.

Evidence in support of Applicants' assertion that the sequence disk of July 1, 2002 was subsequently damaged by treatment of the disk by others following deposit by Applicants can be found by inspection of the USPTO's file copy of the sequence disk filed July 1, 2002. At Applicants' request, Mr. Christopher Lowe, USPTO Quality Assurance Specialist for Technology Center 1600 conducted a visual inspection of the file. Following visual inspection of the sequence disk mailed July 1, 2002, Mr. Lowe indicated to Applicants' Attorneys that the

-4-

Serial No. 10/010,942   ELN-002

disk was "warped" and had "a quarter inch bow in it." It is Applicants' Attorney's understanding that this type of damage is consistent with the irradiation of mail by the United States Postal Service in response to the threat of anthrax poisoning in the Washington D.C. area during the months following the September 11, 2001 terrorist attacks. Sequence disks and other mail submitted to the USPTO in late 2001- mid 2002 were often "damaged" as a result of anthrax irradiation procedures conducted in Lima, Ohio for all mail mailed to the Washington D.C. zip code (20231) of the USPTO (see OG Notice dated January 15, 2002 (Exhibit 16) and Letter dated January 16, 2002 from Commissioner Nicholas P. Godici (Exhibit 17)). Indeed, Applicants' sequence disk was mailed to the 20231 zip code.

As indicated in the OG Notice of January 15, 2002 (Exhibit 16), the USPTO has previously considered mail delays necessitated by the anthrax decontamination process and their effect on Patent Term Adjustment (see Pages 6-8 of Exhibit 16). Where a reply to an Office Action or Notice was mailed on or after October 13, 2001 and no later than December 1, 2001, and where an applicant subsequently received a reduction in Patent Term Adjustment pursuant to 37 C.F.R. §1.704(b) for a delayed receipt of the reply by the USPTO, the USPTO later recognized the mailing date of the reply as a "sufficient showing" that, in spite of all due care, the applicant was unable to reply to the Office Action or Notice within three months of the date of mailing. In these situations, the USPTO saw fit to reinstate applicant's Patent Term Adjustment for any period of delay that exceeded three business days.

Applicants submit that a set of circumstances has occurred in the instant case which are similar to those set forth in Exhibit 16. Here, the evidence indicates that Applicant filed a compliant response including a compliant sequence disk, but that the sequence disk was later damaged by the treatment of others. Given these circumstances, Applicants respectfully submit that they should not be penalized for the 69 day period during which the USPTO mailed a Notice to Comply and Applicants filed a second compliant sequence disk. Applicants submit that they engaged in reasonable efforts to conclude processing of the application by filing a compliant sequence disk on July 1, 2002 which was later rendered defective by circumstances beyond their control. In the alternative, Applicants request reconsideration of the Application for Patent Term Adjustment for either of the following: (i) reinstatement of the 69 day period of adjustment pursuant to 37 C.F.R. §1.705(c) on the grounds that the evidence submitted herewith provides a sufficient showing that, in spite of all due care, the Applicant was unable to respond

-5-

Serial No. 10/010,942   ELN-002

to the Notice to File Missing Parts on July 1, 2002 due to unforeseeable circumstances; or (ii) suspension or waiver of of 37 C.F.R. § 1.704(c)(7) with respect to the 69 day period in view of these circumstances in accordance with 37 C.F.R. §1.183. In any event, Applicants request correction of the period of reduction of 107 days and entry of a new delay period of 38 days as originally requested.

It is Applicants' Attorney's understanding that the filing of the instant Petition is also not a "failure to engage" by Applicants. This understanding is based on a discussion between Applicants' Agent and the Petitions Examiner in which the Examiner informed Applicants' Agent that the issue of whether or not the sequence disk filed July 1, 2002 was compliant is a valid petitionable issue and not a "frivolous" one. It is Applicant's Attorneys' further understanding that the instant petition is effectively part of the original Application for Patent Term Adjustment and is therefore subject to the "safe harbour" provisions of 37 C.F.R. § 1.704(e). Nevertheless, should the USPTO attribute any period of Applicant Delay due to the filing of the instant petition, it is Applicants' understanding that a Certificate of Correction will be issued by the Petitions Examiner to remove this period as Applicant Delay.

Please charge the appropriate fees set forth in 37 C.F.R. §1.705(b) and 37 C.F.R. §1.705(c) to Account No.: 12-0080. However, if any additional fees are determined to be due, the Commissioner is authorized to withdraw such fees from Account No.: 12-0080.

Dated: February 26, 2007   Respectfully submitted,

                                              By _____
                                              Amy E. Mandragouras
                                              Registration No.: 36,207
                                              LAHIVE & COCKFIELD, LLP
                                              28 State Street
                                              Boston, Massachusetts 02109
                                              (617) 227-7400
                                              (617) 742-4214 (Fax)
                                              Attorney/Agent For Applicant

-6-

UNITED STATES PATENT AND TRADEMARK OFFICE

EXHIBIT 1

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450
www.uspto.gov

Paper No.

LAHIVE & COCKFIELD, LLP
ONE POST OFFICE SQUARE
BOSTON MA 02109-2127

COPY MAILED

DEC 2 6 2006

OFFICE OF PETITIONS

In re Application of   :
Basi et al.   :   DECISION ON APPLICATION
Application No. 10/010,942   :   FOR
Filed: December 6, 2001   :   PATENT TERM ADJUSTMENT
Attorney Docket No. ELN-002   :

This is a decision on the "APPLICATION FOR PATENT TERM
ADJUSTMENT INCLUDING REQUEST FOR RECONSIDERATION UNDER 37 CFR
§1.705(b)," filed August 10, 2006. Applicants request that the
determination of patent term adjustment be corrected from zero
(0) days to at least five hundred eight (508) days.

The application for patent term adjustment is **GRANTED to the
extent indicated herein**.

The Office has updated the PAIR screen to reflect that the
correct Patent Term Adjustment (PTA) determination at the time
of the mailing of the Notice of Allowance is ZERO (0) days,
including an additional period of reduction of 12 days for
applicant delay. A copy of the updated PAIR screen, showing the
correct determination, is enclosed.

On May 11, 2006, the Office mailed the Determination of Patent
Term Adjustment under 35 U.S.C. 154(b) in the above-identified
application. The Notice stated that the patent term adjustment
(PTA) to date is 0 days. The instant application for patent
term adjustment was timely filed[1]. Applicants dispute the
reduction of 107 days associated with their filing of a response
on September 16, 2002 to the Notice to File Missing Parts of

---

[1] PALM records indicate that the Issue Fee was received on August 11, 2006.

Application No. 10/010,942   Page 2

Application mailed March 1, 2002. Applicants contend that their
response was filed on July 9, 2002, and thus, the period of
reduction pursuant to 1.704(b) is 38 days.

Applicants disclose that a period of reduction of 12 days should
be entered for their filing of an Information Disclosure
Statement on March 12, 2006. This period has been entered.

37 C.F.R. §1.704(c)(7) provides that a period of reduction is
entered for:

> Submission of a reply having an omission (§1.135(c)), in
> which case the period of adjustment set forth in § 1.703
> shall be reduced by the number of days, if any, beginning
> on the day after the date the reply having an omission
> was filed and ending on the date that the reply or other
> paper correcting the omission was filed.

In this instance, a response was filed on July 9, 2002, three
months and 38 days after the mailing of the Notice. Further,
this response as indicated by the Notice to Comply mailed August
21, 2002, had an omission. On September 16, 2002, 69 days
later, applicant filed the paper correcting the omission.
Accordingly, pursuant to 37 CFR §§ 1.704(b) and 1.704(c)(7), a
total period of 107 days was entered for applicant delay
associated with these two failures to engage.

In view thereof, the correct determination of patent term
adjustment at the time of the mailing of the notice of allowance
is ZERO (0) days.

Receipt of the $200.00 fee set forth in 37 CFR 1.18(e) is
acknowledged. No additional fees are required.

The Office of Patent Publication has been advised of this
decision. The application is thereby forwarded to the Office of
Patent Publication for issuance of the patent. The patent term
adjustment indicated on the patent (as shown on the Issue
Notification mailed about three weeks prior to patent issuance)
will include any additional adjustment accrued both for Office
delay in issuing the patent more than four months after payment
of the issue fee and satisfaction of all outstanding
requirements, and for the Office taking in excess of three years
to issue the patent (to the extent that the three-year period
does not overlap with periods already accorded).

Application No. 10/010,942   Page 3

Telephone inquiries specific to this matter should be directed
to the undersigned at (571) 272-3219.

Nancy Johnson
Senior Petitions Attorney
Office of Petitions

Enclosure: Copy of Revised PAIR Screen

Day : Thursday
Date: 12/21/2006

PALM INTRANET

Time: 07:33:59

PTA Calculations for Application: 10/010942			
Application Filing Date:	12/06/2001	PTO Delay (PTO):	244
Issue Date of Patent:		Three Years:	0
Pre-Issue Petitions:	0	Applicant Delay (APPL):	392
Post-Issue Petitions:	0	Total PTA (days):	0
PTO Delay Adjustment:	-12		

File Contents History					
Number	Date	Contents Description	PTO	APPL	START
110	12/21/2006	ADJUSTMENT OF PTA CALCULATION BY PTO		69	
109	12/21/2006	ADJUSTMENT OF PTA CALCULATION BY PTO		38	
108	12/21/2006	ADJUSTMENT OF PTA CALCULATION BY PTO	73		
107	12/21/2006	ADJUSTMENT OF PTA CALCULATION BY PTO	107		
106	12/21/2006	ADJUSTMENT OF PTA CALCULATION BY PTO		73	
105	12/21/2006	ADJUSTMENT OF PTA CALCULATION BY PTO		12	
85	05/11/2006	MAIL NOTICE OF ALLOWANCE			
84	05/11/2006	MAIL FORMAL DRAWINGS REQUIRED			
83	05/11/2006	MAIL EXAMINER INTERVIEW SUMMARY (PTOL - 413)			
82	05/10/2006	ISSUE REVISION COMPLETED			
81	05/10/2006	FORMAL DRAWINGS REQUIRED			
80	05/10/2006	NOTICE OF ALLOWANCE DATA VERIFICATION COMPLETED			
79	05/10/2006	CASE DOCKETED TO EXAMINER IN GAU			
78	05/10/2006	NOTICE OF ALLOWABILITY			
77	04/24/2006	EXAMINER INTERVIEW SUMMARY RECORD (PTOL - 413)			
76	05/01/2006	MAIL EXAMINER INTERVIEW SUMMARY (PTOL - 413)			
75	04/11/2006	EXAMINER INTERVIEW SUMMARY RECORD (PTOL - 413)			
74	03/15/2006	INFORMATION DISCLOSURE STATEMENT CONSIDERED			
73	03/03/2006	INFORMATION DISCLOSURE STATEMENT CONSIDERED			
72	12/22/2005	INFORMATION DISCLOSURE STATEMENT CONSIDERED			

71	03/15/2006	REFERENCE CAPTURE ON IDS			
70	03/15/2006	INFORMATION DISCLOSURE STATEMENT (IDS) FILED			
69	03/03/2006	NEW OR ADDITIONAL DRAWING FILED			
68	03/13/2006	DATE FORWARDED TO EXAMINER			
67	03/03/2006	RESPONSE AFTER NON-FINAL ACTION		59	59
66	03/03/2006	REQUEST FOR EXTENSION OF TIME - GRANTED			
65	03/03/2006	REFERENCE CAPTURE ON IDS			
64	03/03/2006	INFORMATION DISCLOSURE STATEMENT (IDS) FILED			
63	02/22/2006	MAIL EXAMINER INTERVIEW SUMMARY (PTOL - 413)			
62	02/16/2006	EXAMINER INTERVIEW SUMMARY RECORD (PTOL - 413)			
61	12/22/2005	REFERENCE CAPTURE ON IDS			
60	12/22/2005	INFORMATION DISCLOSURE STATEMENT (IDS) FILED			
59	10/03/2005	MAIL NON-FINAL REJECTION	14		47
58	09/29/2005	NON-FINAL REJECTION			
57	08/24/2005	CASE DOCKETED TO EXAMINER IN GAU			
56	06/28/2005	CASE DOCKETED TO EXAMINER IN GAU			
55	05/24/2005	INFORMATION DISCLOSURE STATEMENT (IDS) FILED		5	47
54	06/02/2005	IFW TSS PROCESSING BY TECH CENTER COMPLETE			
53	06/02/2005	CASE DOCKETED TO EXAMINER IN GAU			
52	11/29/2004	REFERENCE CAPTURE ON IDS			
51	11/29/2004	INFORMATION DISCLOSURE STATEMENT (IDS) FILED			
50	05/24/2005	REFERENCE CAPTURE ON IDS			
48	06/01/2005	DATE FORWARDED TO EXAMINER			
47	05/19/2005	RESPONSE AFTER NON-FINAL ACTION		30	44
46	05/19/2005	REQUEST FOR EXTENSION OF TIME - GRANTED			
45	05/25/2005	CASE DOCKETED TO EXAMINER IN GAU			
44	01/19/2005	MAIL NON-FINAL REJECTION			
43	01/19/2005	NON-FINAL REJECTION			
42	12/16/2004	INFORMATION DISCLOSURE STATEMENT (IDS) FILED		20	38

41	12/20/2004	DATE FORWARDED TO EXAMINER			
40	12/14/2004	SUPPLEMENTAL RESPONSE			
39	12/07/2004	DATE FORWARDED TO EXAMINER			
38	11/26/2004	RESPONSE AFTER NON-FINAL ACTION		92	35
37	11/26/2004	REQUEST FOR EXTENSION OF TIME - GRANTED			
36	11/26/2004	WORKFLOW INCOMING AMENDMENT IFW			
35	05/26/2004	MAIL NON-FINAL REJECTION			
34	05/25/2004	NON-FINAL REJECTION			
33	03/18/2004	DATE FORWARDED TO EXAMINER			
32	03/12/2004	RESPONSE TO ELECTION / RESTRICTION FILED		79	26
29	03/12/2004	REQUEST FOR EXTENSION OF TIME - GRANTED			
28	12/19/2003	CORRESPONDENCE ADDRESS CHANGE			
27	09/20/2003	PRELIMINARY AMENDMENT			
26	09/24/2003	MAIL RESTRICTION REQUIREMENT	230		-1
25	09/24/2003	REQUIREMENT FOR RESTRICTION / ELECTION			
24	09/17/2003	CASE DOCKETED TO EXAMINER IN GAU			
23	10/03/2002	INFORMATION DISCLOSURE STATEMENT (IDS) FILED			
22	07/09/2002	PRELIMINARY AMENDMENT			
21	05/27/2003	CASE DOCKETED TO EXAMINER IN GAU			
20	04/21/2003	CASE DOCKETED TO EXAMINER IN GAU			
19	10/11/2002	APPLICATION DISPATCHED FROM OIPE			
18	10/10/2002	APPLICATION IS NOW COMPLETE			
17	09/16/2002	ADDITIONAL APPLICATION FILING FEES		107	8
16	09/16/2002	CRF DISK HAS BEEN RECEIVED BY PREEXAM / GROUP / PCT			
15	10/07/2002	CRF IS GOOD TECHNICALLY / ENTERED INTO DATABASE			
14	08/25/2002	RECEIPT OF ALL ACKNOWLEDGEMENT LETTERS			
13	08/21/2002	SEQUENCE ERRORS			
12	07/01/2002	PAYMENT OF ADDITIONAL FILING FEE/PREEXAM			
11	07/01/2002	CRF DISK HAS BEEN RECEIVED BY PREEXAM / GROUP / PCT			
10	07/01/2002	A STATEMENT BY ONE OR MORE INVENTORS SATISFYING THE REQUIREMENT UNDER 35 USC 115, OATH OF THE APPLIC			

9	07/30/2002	CRF DOES NOT MATCH APPLICATION SPECIFICATION -- APPLICANT MUST CORRECT				
8	03/01/2002	NOTICE MAILED--APPLICATION INCOMPLETE--FILING DATE ASSIGNED				
6	01/15/2002	REFERRED BY L&R FOR THIRD-LEVEL SECURITY REVIEW. AGENCY REFERRAL LETTER GENERATED				
5	01/10/2002	IFW SCAN & PACR AUTO SECURITY REVIEW				
4	01/04/2002	CRF IS FLAWED TECHNICALLY / NOT ENTERED INTO DATABASE				
3	12/19/2001	IFW SCAN & PACR AUTO SECURITY REVIEW				
2	12/06/2001	CRF DISK HAS BEEN RECEIVED BY PREEXAM / GROUP / PCT				
1	12/06/2001	INITIAL EXAM TEAM NN				

Search Another: Application# | Search |

EXPLANATION OF PTA CALCULATION

EXPLANATION OF PTE CALCULATION

To go back use Back button on your browser toolbar

Back to PALM | ASSIGNMENT | OASIS | Home page

EXHIBIT 2

Docket No.: ELN-002
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Guriq Basi et al.

Application No.: 10/010942   Confirmation No.: 5594

Filed: December 6, 2001   Art Unit: 1649

For: HUMANIZED ANTIBODIES THAT   Examiner: Ballard, Kimberly A.
      RECOGNIZE BETA AMYLOID PEPTIDE

MS Petition
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

STATEMENT UNDER 37 CFR § 1.702(b)(2)

Dear Sir:

1.   This statement is respectfully submitted in support of the "Application for Patent Term
Adjustment Including Request for Reconsideration Under 37 CFR §1.705(b)" for the above-
referenced application. In view of the following, it is respectfully requested that Applicants be
granted a minimum patent term adjustment of **508 days**, with an additional term to be added
based on the number of days following payment of the issue fee on August 11, 2006 to the date
of issuance of a patent for the above-referenced application.

2.   The patent term adjustment on the Determination of Patent Term Adjustment Under 35
U.S.C. §154(b) ("PTAS Sheet") that was attached to the Notice of Allowance is 0 days (a copy
of the PTAS Sheet is submitted herewith as Exhibit A). This determination of 0 days is in error
in that pursuant to 35 U.S.C. §154(b) the Office failed to take certain action within the time
frame specified in 37 CFR §1.702(a) and failed to issue a patent within three years of the actual
filing date of the above-referenced application in accordance with 37 CFR §1.702(b).

Page 1 of 9

Pursuant to 37 CFR §1.703(a), Applicants are entitled to a period of patent term adjustment due to the failure by the Office to mail an action under 35 U.S.C. §132 not later than 14 months after the actual filing date (i.e., by February 6, 2003) (hereinafter "14 Month Delay"). As the Office failed to mail an action under 35 U.S.C. §132 until September 24, 2003, Applicants are entitled to a period of patent term adjustment beginning on the day after the date that is 14 months after the date on which the above-referenced application was filed under 35 U.S.C. §111(a), i.e., February 7, 2003, and ending on the date of mailing of an action under 35 U.S.C. §132, i.e., September 24, 2003. Accordingly, the period of patent term adjustment due to the 14 Month Delay by the Office is 230 days, which is in agreement with the period calculated by the Office on the PTAS Sheet (Exhibit A, line 25).

In addition to the patent term adjustment due to the 14 Month Delay, pursuant to 37 CFR §1.703(b) Applicants are entitled to a period of patent term adjustment due to examination delay from the number of days in the period beginning on the day after the date that is three years after the date on which the above-referenced application was filed under 35 U.S.C. §111(a), i.e., December 7, 2004, and ending on the date a patent is issued, (hereinafter "Three Years Delay"). As the issue date has yet to be determined, Applicants have calculated a minimum period of Three Years Delay of 613 days, based on a hypothetical issue date of August 11, 2006, the projected date of payment of the issue fee.

As set forth in 37 CFR §1.703(f), Applicants are entitled to a period of patent term adjustment equal to the period of examination delays based on the grounds set forth in 37 CFR §1.702 reduced by the period of time equal to the period of time during which Applicants failed to engage in reasonable efforts to conclude prosecution pursuant to 37 CFR §1.704 (hereinafter "Applicant Delay"). With respect to the above-referenced application, the total period of examination delays is the sum of the period of 14 Month Delay (230 days) and the minimum period of Three Years Delay (613 days), or 843 days, to the extent these periods of delay are not overlapping. As the period of 14 Month Delay ended on November 24, 2003, prior to the first day of the period of Three Years Delay, i.e., December 7, 2004, Applicants submit that these periods are not overlapping. To calculate the period of patent term adjustment, the total period

Page 2 of 9

USSN 10/010,942   Group Art Unit: 1649

of examination delay is reduced by the period of Applicant Delay, which Applicants have calculated herein as a period of 335 days (not 392 days as set forth in the PTAS Sheet (Exhibit A)).

Accordingly, Applicants submit that the correct patent term adjustment for the above-referenced application is at least 508 days, which is the difference between the total period of examination delay (843 days) and the period of Applicant Delay (335 days). Applicants further submit that the term of 508 days should be extended by an additional term equal to the number of days following payment of the issue fee on August 11, 2006 to the date of issuance of a patent for the above-referenced application in accordance with 37 CFR §1.703(b). As such, the correct patent term adjustment upon issuance of a patent is expected to be the sum of 508 days (as calculated herein) and the number of days from August 12, 2006 to issuance of a patent.

3.   The factual bases for the above adjustment are set forth as follows:

A.   Examination Delays Pursuant to 37 CFR §1.702 and §1.703

Pursuant to 37 CFR §1.703(f), the period of adjustment of the term of the patent under §1.702 is the sum of the periods of examination delay calculated under subparagraphs (a)-(e), to the extent that such periods are not overlapping, less the sum of the periods calculated under §1.704 (the period of Applicant Delay). In the above-referenced application, Applicants are entitled to a period of examination delay equal to the sum of the periods of delay under §1.703(a) and (b) for the reasons set forth below.

(i)   "14 Month Delay" Pursuant to §1.703(a)(1)

In accordance 37 CFR §1.703(a)(1), Applicants are entitled to a period of patent term adjustment due to the failure by the Office to mail an action under 35 U.S.C. §132 not later than 14 months after the actual filing date (i.e., by February 6, 2003). As shown in the PTAS Sheet (Exhibit A, line 25), the Office failed to mail an action under 35 U.S.C. §132 (a Restriction

Page 3 of 9

USSN 10/010,942   Group Art Unit: 1649

Requirement) until September 24, 2003. As such, Applicants are entitled to a period of patent term adjustment beginning February 7, 2003 and ending on September 24, 2003, the date of mailing of the Restriction Requirement by the Office. Accordingly, the period of patent term adjustment due to the 14 Month Delay by the Office is 230 days, as shown on line 25 of the PTAS Sheet (Exhibit A, line 25).

(ii)   "Three Years Delay" Pursuant to 37 CFR §1.703(b)

It is anticipated that the Office will not comply with the requirement of 35 U.S.C. §154(b) and 37 CFR §1.702(b), which requires issuance of a patent within 3 years after the date on which the application was filed under 35 U.S.C. §111(a). As indicated in the Notice of Allowance, a patent is projected to issue on November 28, 2006, but may issue earlier or later depending on the circumstances of publication. However, even assuming arguendo that a patent is issued on the same day as the projected date of payment of the issue fee (*i.e.*, August 11, 2006), said issue date would be 3 years and 613 days after the date on which the above-referenced application was filed under 35 U.S.C. §111(a). As none of the exclusionary periods set forth in 37 CFR §1.702(b) apply to the instant application and in accordance with 37 CFR §1.703, a minimum period of examination delay is calculated to be at least 613 days, based on the hypothetical issue date of August 11, 2006. This minimum period of examination delay is to be extended by an additional term equal to the number of days following payment of the issue fee on August 11, 2006 to the date of issuance of a patent. Accordingly, the entire period of Three Years Delay is the sum of the minimum period of examination delay of 613 days and the number of days from August 12, 2006 to the day of issuance of the patent.

(iii)   Total Examination Delay Pursuant to 37 CFR §1.703(f)

As set forth in 37 CFR §1.703(f), the period of examination delay based on the grounds set forth in 37 CFR §1.702 is the sum of the period of 14 Month Delay (230 days) and the minimum period of Three Years Delay (613 days), or 843 days, to the extent these periods of delay are not overlapping. As the period of 14 Month Delay ended on November 24, 2003, prior to the first day of the period of Three Years Delay, *i.e.*, December 7, 2004, Applicants submit that these periods are not overlapping.

Page 4 of 9

USSN 10/010,942   Group Art Unit: 1649

B.   "Applicant Delay" Pursuant to 37 CFR §1.704

Pursuant to 37 CFR §1.704 the period of adjustment of the term of the patent due to
examination delay is reduced by the period of Applicant Delay. As indicated on the PTAS Sheet
(Exhibit A), the Office has calculated a period of Applicant Delay of 392 days. Applicants
respectfully submit that the correct period of Applicant Delay is 335 days and seek correction
based on the following remarks. A PTAS Sheet showing corrections by Applicants is submitted
herewith as Exhibit C. A copy of the "Image File Wrapper Record" and "Transaction History"
from Applicants' Private PAIR are submitted herewith as Exhibits B and F.

(i) Applicant Delay for Responding to a Notice to File Missing Parts of March 1, 2002

Applicants request correction of the initial period of Applicant Delay of 107 days (line 16
of Exhibit A) from the date of mailing of a Notice to File Missing Parts of the Application on
March 1, 2002 (line 7 of Exhibit A) to September 16, 2002 (line 16 of Exhibit A), the date on
which Applicants are alleged to have responded. Applicants submit that the correct period of
Applicant Delay is 38 days, which is the number of days in excess of 3 months from the date of
the Notice to File Missing Parts (i.e., June 1, 2002) to the date on which a complete response
was filed by the Applicants (i.e., July 9, 2002). As evidenced by the enclosed copy of a postcard
receipt (submitted herewith as Exhibit D), Applicants filed a complete response to the Notice to
File Missing Parts, including a computer-readable sequence disk, via first class mail on July 1,
2002. The date-in stamp on the postcard receipt indicates that these documents and sequence
disk were received by the Office on July 9, 2002. Copies of the Notice to File Missing Parts
from March 1, 2002 as well as Applicants' response thereto from the Image File Wrapper
Record are submitted herewith as Exhibit E. Additional evidence of receipt of Applicants'
complete response on July 9, 2002 is shown on the Image File Wrapper Record (Exhibit B) from
this date indicating "Applicant Response to Pre-Exam Formalities Notice", "Oath or Declaration
Filed" and "CFR Sequence Listing Filed," among other entries. According to 37 CFR §1.704
(b), the period of Applicant Delay begins on the day that is 3 months after the date of the Notice
to Comply (i.e., June 2, 2002) and ends on the date the reply was filed by Applicants (i.e., July 9,
2002) for a total of 38 days. For the reasons set forth in subsection B (ii) below, Applicants

Page 5 of 9

submit that no other Applicant Delays accrued during the period from March 1, 2002 to September 16, 2002. As such, Applicants request correction of the initial period of Applicant Delay of <u>107 days</u> (line 16 of Exhibit A) to <u>38 days</u> (line 12 of Exhibit C).

(ii) Applicant Delay for Responding to a Notice to Comply with Sequence Listing of August 21, 2002

Applicants respectfully submit that the Office has improperly calculated the period beginning August 22, 2002 (the day following the mail date of a "Preexam Formalities Notice" by the Office on August 21, 2002 (line 12 of Exhibit A)) and ending September 16, 2002 (the date of a response to the Preexam Formalities Notice by Applicants (line 16 of Exhibit A) as an Applicant Delay. This alleged period of delay corresponds to the period for response by Applicants to a "Preexam Formalities Notice," a "Notice to Comply with Requirement for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures" ("Notice to Comply with Sequence Listing") mailed August 21, 2002 (a copy of this Notice and Applicants response is submitted herewith as Exhibit G). As shown in Exhibit G, Applicants filed a response to the Notice to Comply with Sequence Listing via first class mail on September 16, 2002. The date-in stamp by the Office indicates that the response was received on September 20, 2002. Further evidence of receipt of Applicants' complete response on September 20, 2002 is shown on the Image File Wrapper Record (Exhibit B) from this date indicating "Response to Pre-Exam Sequence Notice" and "Sequence Listing," among other entries. Pursuant to 37 CFR §1.704(b), the period of Applicant Delay begins on the day that is 3 months after the date of the Notice to Comply with Sequence Listing (*i.e.*, November 22, 2002) and ends on the date the reply was filed by Applicants. As Applicants filed a complete response to the Notice to Comply with Sequence Listing on September 20, 2002, within the three month grace period provided by 37 CFR §1.704(b), no Applicant Delay accrued.

Finally, it is respectfully submitted that the period of time from July 9, 2002 (the date of response by Applicants to the Notice to File Missing Parts) to August 21, 2002 (the date of mailing of the Notice to Comply with Sequence Listing by the Office) has been improperly calculated by the Office as a period of Applicant Delay. The alleged period of delay, a total of

Page 6 of 9

USSN 10/010,942   Group Art Unit: 1649

43 days, corresponds to the time taken by the Office of Initial Patent Examination (OIPE) to process the response filed by Applicants on July 9, 2002. Applicants submit that the 43 day period is an examination delay by the Office and is not a delay by the Applicants pursuant to 37 CFR §1.704.

In view of the preceding remarks, Applicants submit that no Applicant Delays accrued during the period from July 9, 2002 to September 20, 2002. Accordingly, Applicants request correction of the initial period of Applicant Delay of _107 days_ (line 16 of Exhibit A) to _38 days_ (line 12 of Exhibit C), which is equivalent to the period of Applicant Delay beginning on the day that is 3 months after the date of the Notice to Comply (*i.e.*, June 2, 2002) and ending on the date the reply was filed by Applicants (*i.e.*, July 9, 2002).

(iii) Applicant Delay for Filing an Information Disclosure Statement

Applicants respectfully submit that an additional period of Applicant Delay of _12 days_ accrued for the delayed submission of an Information Disclosure Statement (IDS) on March 15, 2006 (see line 66, Exhibit C). This period is not shown on Exhibit A, the PTAS Sheet from the Office. As shown on Exhibit C, an IDS was filed without a statement under 37 CFR §1.704(d), 12 days after the filing of a response by Applicants to an office action on March 3, 2006. Pursuant to 37 CFR §1.704(c), this 12 day period should be considered an Applicant Delay and should be added to the period of delay by Applicants.

(iv)   Other Entries Which Do Not Add to the Period of Applicant Delay

Applicants submit that there are several inconsistencies between entries shown on the PTAS Sheet (Exhibit A) and those shown on the Image File Wrapper Record (Exhibit B). In particular, Applicants direct the attention of the Office to Applicants' Petition to Correct Inventorship under 37 CFR §1.48(a) and accompanying Oath and Declaration filed on April 3, 2006. The Oath and Declaration is shown on Exhibit B, but does not appear on the PTAS Sheet (Exhibit A). According to MPEP 2732, oaths and declarations are examples of "other paper" that may generate reductions pursuant to 37CFR §1.704(c) (10) if such papers are filed _after_ a Notice of Allowance is mailed or given. However, as Applicants filed the Oath and Declaration

Page 7 of 9

USSN 10/010,942   Group Art Unit: 1649

on April 3, 2006, well before the Notice of Allowance mail date of May 11, 2006, and this submission is not believed to otherwise delay the processing or examination of the application (as evidenced by the issuance of a Notice of Allowance 38 days following receipt of the Oath and Declaration), it is not believed to be an Applicant Delay as defined by 37 CFR §1.704.

In addition to these inconsistencies, Applicants also wish to point out that the entries of May 10, 2006 and May 11, 2006 on the PTAS sheet entitled "Formal Drawings Required" and "Mail Formal Drawings Required," respectively, are erroneous. These entries do not appear in the Image File Wrapper Record (Exhibit B) and Applicants did not receive a paper copy of a request for formal drawing from the Office. Applicants contacted Examiner Ballard on August 1, 2006, in which she confirmed that she did not issue a notice for formal drawings and that the entry on the PTAS Sheet was erroneous. Applicants were informed by the Examiner that the Office would seek appropriate correction of these erroneous entries related to formal drawings. As shown in the Transaction History from Applicants Private PAIR (Exhibit F), the Office entered "Correction-Drawing NOT required" on August 8, 2006, thereby acknowledging the erroneous entry in the PTAS Sheet. The preceding inconsistencies in the PTAS Sheet are noted in Exhibit C and appropriate correction by the Office is respectfully requested.

(v)   Calculation of the Total Period of Applicant Delay

In view of the above, Applicants have calculated a total period of Applicant Delay of 335 days which is the sum of the following Applicant Delays shown in Exhibit C: (i) the 38 day period from June 2, 2002 to July 9, 2002 (lines 9-11); (ii) the 79 day period (line 29); (iii) the 92 day period (line 35); (iii) the 20 day period (line 39); (iv) the 30 day period (line 44); (v) the 5 day period (line 51); (vi) the 59 day period (line 63); and (vii) the 12 day period from March 3, 2006 to March 15, 2006 (lines 63-66). Applicants respectfully submit that the correct period of Applicant Delay is 335 days, not 392 days, and request appropriate correction by the Office.

Page 8 of 9

C. Calculation of Correct Patent Term Adjustment Pursuant to 37 CFR §1.702(f)

As set forth in 37 CFR §1.703(f), Applicants are entitled to a period of patent term adjustment equal to the period of examination delays reduced by the period of Applicant Delay. Therefore, Applicants submit that the correct patent term adjustment for the above-referenced application is at least 508 days, which is the difference between the total period of examination delay (843 days) and the period of Applicant Delay (335 days). Applicants further submit that the term of 508 days should be extended by an additional term equal to the number of days following payment of the issue fee on August 11, 2006 to the date of issuance of a patent for the above-referenced application in accordance with 37 CFR §1.703(b). As such, the correct patent term adjustment upon issuance of a patent is expected to be the sum of 508 days (as calculated herein) and the number of days from August 12, 2006 to issuance of a patent.

4. In accordance with 37 CFR§1.705(b)(2)(iii), Applicants submit that the pending patent corresponding to this application will not be subject to a terminal disclaimer.

In view of the foregoing, it is respectfully requested that this Application for Patent Term Adjustment be favorably considered and that a corrected Determination of Patent Term Adjustment be issued to reflect a minimum patent term adjustment of 508 days, with an additional term to be added based on the number of days following payment of the issue fee on August 11, 2006 to the date of issuance of a patent for the above-referenced application.

Dated: August 10, 2006   Respectfully submitted,

                                          By
                                          Amy E. Mandragouras, Esq
                                          Registration No.: 36,207
                                          LAHIVE & COCKFIELD, LLP
                                          28 State Street
                                          Boston, Massachusetts 02109
                                          (617) 227-7400
                                          (617) 742-4214 (Fax)
                                          Attorney For Applicant

EXHIBIT 3

UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/010,942	12/06/2001	Guriq Basi	ELN-002

CONFIRMATION NO. 5594

000959
LAHIVE & COCKFIELD
28 STATE STREET
BOSTON, MA 02109

FORMALITIES LETTER

OC000000008658514

Date Mailed: 08/21/2002

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d). Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- **For Rules Interpretation, call (703) 308-4216**
- **To Purchase PatentIn Software, call (703) 306-2600**
- **For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov**

*A copy of this notice **MUST** be returned with the reply.*

Customer Service Center
Initial Patent Examination Division (703) 308-1202
PART 3 - OFFICE COPY

OIPE

CRF Problem Report

The Scientific and Technical Information Center (STIC) experienced a problem when processing the following computer readable form (CRF):

Application Serial Number: _10/010,942 A_
Filing Date: _12/06/2001_
Date Processed by STIC: _7/24/2002_

STIC Contact: **Mark Spencer, 703-308-4212**

Nature of Problem:

The CRF (was):

___ (circle one) Damaged or Unreadable (for Unreadable, see attached)
___ Blank (no files on CRF) (see attached)
___ Empty file (filename present, but no bytes in file) (see attached)
___ Virus-infected. Virus name: _____ The STIC will not process the CRF.
___ Not saved in ASCII text
___ Sequence Listing was embedded in the file. According to Sequence Rules,
        submitted file should only be the Sequence Listing.
___ Did not contain a Sequence Listing. (see attached sample)
___ Other: _____

PLEASE USE THE CHECKER VERSION 3.1 PROGRAM TO REDUCE ERRORS.
SEE BELOW FOR ADDRESS:
        http://www.uspto.gov/web/offices/pac/checker

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail. Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

1. EFS-Bio (<http://www.uspto.gov/ebc/efs/downloads/documents.htm>, EFS Submission User Manual - ePAVE)
2. U.S. Postal Service: U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202
3. Hand Carry directly to:
    U.S. Patent and Trademark Office, Technology Center 1600, Reception Area, 7th Floor, Examiner Name, Sequence Information, Crystal Mall One, 1911 South Clark Street, Arlington, VA 22202
        Or
    U.S. Patent and Trademark Office, Box Sequence, Customer Window, Lobby, Room 1B03, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202
4. Federal Express, United Parcel Service, or other delivery service to: U.S. Patent and Trademark Office, Box Sequence, Room 1B03-Mailroom, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202

Revised 01/29/2002

UNITED STATES PATENT AND TRADEMARK OFFICE

ATTACHMENT TO "NOTICE TO COMPLY WITH REQUIREMENTS...SEQUENCE DISCLOSURES"

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be submitted using one of the following methods:

1. Electronically submitted through EFS-Bio (http://www.uspto.gov/ebc/efs/downloads/documents.htm, EFS Submission User Manual - ePAVE)

2. Mailed to:
   U.S. Patent and Trademark Office
   Box Sequence, P.O. Box 2327
   Arlington, VA 22202

3. Mailed by Federal Express, United Parcel Service or other delivery service to:
   U. S. Patent and Trademark Office
   2011 South Clark Place
   Customer Window, Box Sequence
   Crystal Plaza Two, Lobby, Room 1B03
   Arlington, Virginia 22202

4. Hand Carried directly to the Customer Window at:
   2011 South Clark Place
   Crystal Plaza Two, Lobby, Room 1B03, Box Sequence,
   Arlington, Virginia 22202

Rev. 12/27/2001

EXHIBIT 4

Office No. ____ELN-002

THE "RECEIVED" STAMP OF THE PATENT AND TRADEMARK OFFICE IMPRINTED HEREON ACKNOWLEDGES THE FILING OF:

Description of Paper* and No.: Transmittal Letter (1 page, in duplicate); Request for Two-Month Extension of Time (1 page, in duplicate); Response to Notice to File Missing Parts (2 pages, in duplicate); executed Declaration, Petition and Power of Attorney document (5 pages); Copy of Notice to File Missing Parts (5 pages); Preliminary Amendment (22 pages with Appendix A); Transmittal Letter for Diskette containing Substitute Sequence Listing (1 page); 21 pages of Substitute Sequence Listing; and acknowledgment postcard. Diskette containing computer readable form of the Sequence Listing;

Title: *Humanized Antibodies That Recognize Beta Amyloid Peptide*

Name of Applicant(s): Guriq Basi, Jose Saldanha, and Ted Yednock

Intl. or Serial No.: 10/010,942   **Date:** July 1, 2002

Attorneys: AEM/DJM/CEH

with Certificate of First Class Mailing

JUL 0 9 2002
OIPE
PATENT & TRADEMARK OFFICE

=0.37= U.S. POSTAGE

PB METER
7107161

BOSTON
MA

NO POSTAGE STAMP NECESSARY
POSTAGE HAS BEEN PREPAID BY

LAHIVE & COCKFIELD, LLP
28 STATE STREET
BOSTON, MA 02109

RECEIVED
LAHIVE

JUN 15 2007

RETRIE
FORWARDED

02109+1784 07

EXHIBIT 5

LAHIVE & COCKFIELD, LLP
28 State Street
Boston MA 02109

SEQUENCE LISTING UNDER 37 CFR 1.825
(CORRECTED SEQUENCE)

Applicants: Basi. Guriq et al
Serial No.   10/010 942
Filed: 2001-12-06
For: HUMANIZED ANTIBODIES THAT
RECOGNIZE BETA-AMYLOID PEPTIDE
Copy Lahive & Cockfield, LLP
Docket No ELN-002   Date July 1. 2002

3 5" Diskette 1.44 MB   IBM-PC MS-Windows

ELN-002   EXHIBIT 6

                              SEQUENCE LISTING

       <110> Basi, Guriq
             Saldanha, Jose
             Yednock, Ted

       <120> HUMANIZED ANTIBODIES THAT RECOGNIZE
             BETA-AMYLOID PEPTIDE

       <130> ELN-002

       <140> US 10/010,942
       <141> 2001-12-06

       <150> US 60/251,892
       <151> 2000-12-06

       <160> 63

       <170> FastSEQ for Windows Version 4.0

       <210> 1
       <211> 396
       <212> DNA
       <213> Mus musculus

       <220>
       <221> CDS
       <222> (1)...(396)

       <221> sig_peptide
       <222> (1)...(60)

       <400> 1
       atg atg agt cct gcc cag ttc ctg ttt ctg tta gtg ctc tgg att cgg   48
       Met Met Ser Pro Ala Gln Phe Leu Phe Leu Leu Val Leu Trp Ile Arg
       -20   -15   -10   -5

       gaa acc aac ggt tat gtt gtg atg acc cag act cca ctc act ttg tcg   96
       Glu Thr Asn Gly Tyr Val Val Met Thr Gln Thr Pro Leu Thr Leu Ser
                       1   5   10

       gtt acc att gga caa cca gcc tcc atc tct tgc aag tca agt cag agc   144
       Val Thr Ile Gly Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser
                   15   20   25

       ctc tta gat agt gat gga aag aca tat ttg aat tgg ttg tta cag agg   192
       Leu Leu Asp Ser Asp Gly Lys Thr Tyr Leu Asn Trp Leu Leu Gln Arg
            30   35   40

       cca ggc cag tct cca aag cgc cta atc tat ctg gtg tct aaa ctg gac   240
       Pro Gly Gln Ser Pro Lys Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp
        45   50   55   60

       tct gga gtc cct gac agg ttc act ggc agt gga tca ggg aca gat ttt   288
       Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe
                        65   70   75

       aca ctg aaa atc agc aga ata gag gct gag gat ttg gga ctt tat tat   336
       Thr Leu Lys Ile Ser Arg Ile Glu Ala Glu Asp Leu Gly Leu Tyr Tyr
                       80   85   90

       tgc tgg caa ggt aca cat ttt cct cgg acg ttc ggt gga ggc acc aag   384
       Cys Trp Gln Gly Thr His Phe Pro Arg Thr Phe Gly Gly Gly Thr Lys

                                      1

ELN-002


```
Cys Trp Gln Gly Thr His Phe Pro Arg Thr Phe Gly Gly Gly Thr Lys
        95                100               105

ctg gaa atc aaa                                                          396
Leu Glu Ile Lys
    110
```


<210> 2
<211> 132
<212> PRT
<213> Mus musculus

<220>
<221> SIGNAL
<222> (1)...(20)

<400> 2
```
Met Met Ser Pro Ala Gln Phe Leu Phe Leu Leu Val Leu Trp Ile Arg
-20             -15             -10             -5
Glu Thr Asn Gly Tyr Val Val Met Thr Gln Thr Pro Leu Thr Leu Ser
                 1           5                   10
Val Thr Ile Gly Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser
        15              20              25
Leu Leu Asp Ser Asp Gly Lys Thr Tyr Leu Asn Trp Leu Leu Gln Arg
    30              35              40
Pro Gly Gln Ser Pro Lys Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp
45              50              55              60
Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe
                 65                  70                  75
Thr Leu Lys Ile Ser Arg Ile Glu Ala Glu Asp Leu Gly Leu Tyr Tyr
            80              85                  90
Cys Trp Gln Gly Thr His Phe Pro Arg Thr Phe Gly Gly Gly Thr Lys
        95                100               105
Leu Glu Ile Lys
    110
```


<210> 3
<211> 414
<212> DNA
<213> Mus musculus

<220>
<221> CDS
<222> (1)...(414)

<221> sig_peptide
<222> (1)...(57)

<400> 3
```
atg aac ttc ggg ctc agc ttg att ttc ctt gtc ctt gtt tta aaa ggt    48
Met Asn Phe Gly Leu Ser Leu Ile Phe Leu Val Leu Val Leu Lys Gly
                -15             -10                 -5

gtc cag tgt gaa gtg aag ctg gtg gag tct ggg gga ggc tta gtg aag    96
Val Gln Cys Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Lys
            1               5                   10

cct gga gcg tct ctg aaa ctc tcc tgt gca gcc tct gga ttc act ttc   144
Pro Gly Ala Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe
        15              20              25
```


2

ELN-002

```
agt aac tat ggc atg tct tgg gtt cgc cag aat tca gac aag agg ctg    192
Ser Asn Tyr Gly Met Ser Trp Val Arg Gln Asn Ser Asp Lys Arg Leu
 30              35              40              45

gag tgg gtt gca tcc att agg agt ggt ggt ggt aga acc tac tat tca    240
Glu Trp Val Ala Ser Ile Arg Ser Gly Gly Gly Arg Thr Tyr Tyr Ser
             50              55              60

gac aat gta aag ggc cga ttc acc atc tcc aga gag aat gcc aag aac    288
Asp Asn Val Lys Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn
         65              70              75

acc ctg tac ctg caa atg agt agc ctg aag tct gag gac acg gcc ttg    336
Thr Leu Tyr Leu Gln Met Ser Ser Leu Lys Ser Glu Asp Thr Ala Leu
         80              85              90

tat tat tgt gtc aga tat gat cac tat agt ggt agc tcc gac tac tgg    384
Tyr Tyr Cys Val Arg Tyr Asp His Tyr Ser Gly Ser Ser Asp Tyr Trp
         95              100             105

ggc cag ggc acc act gtc aca gtc tcc tca                            414
Gly Gln Gly Thr Thr Val Thr Val Ser Ser
110             115
```

```
<210> 4
<211> 138
<212> PRT
<213> Mus musculus

<220>
<221> SIGNAL
<222> (1)...(19)

<400> 4
Met Asn Phe Gly Leu Ser Leu Ile Phe Leu Val Leu Val Leu Lys Gly
             -15             -10             -5
Val Gln Cys Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Lys
             1               5               10
Pro Gly Ala Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe
         15              20              25
Ser Asn Tyr Gly Met Ser Trp Val Arg Gln Asn Ser Asp Lys Arg Leu
30              35              40              45
Glu Trp Val Ala Ser Ile Arg Ser Gly Gly Gly Arg Thr Tyr Tyr Ser
             50              55              60
Asp Asn Val Lys Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn
         65              70              75
Thr Leu Tyr Leu Gln Met Ser Ser Leu Lys Ser Glu Asp Thr Ala Leu
         80              85              90
Tyr Tyr Cys Val Arg Tyr Asp His Tyr Ser Gly Ser Ser Asp Tyr Trp
         95              100             105
Gly Gln Gly Thr Thr Val Thr Val Ser Ser
110             115


<210> 5
<211> 132
<212> PRT
<213> Artificial Sequence

<220>
<221> SIGNAL
<223> (1)...(20)
```

3

ELN-002

<223> humanized 3D6 light chain variable region

<400> 5
Met Met Ser Pro Ala Gln Phe Leu Phe Leu Leu Val Leu Trp Ile Arg
-20   -15   -10   -5
Glu Thr Asn Gly Tyr Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro
                1   5   10
Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser
        15   20   25
Leu Leu Asp Ser Asp Gly Lys Thr Tyr Leu Asn Trp Leu Leu Gln Lys
        30   35   40
Pro Gly Gln Ser Pro Gln Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp
45   50   55   60
Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe
                65   70   75
Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr
            80   85   90
Cys Trp Gln Gly Thr His Phe Pro Arg Thr Phe Gly Gln Gly Thr Lys
        95   100   105
Val Glu Ile Lys
    110

<210> 6
<211> 125
<212> PRT
<213> Homo sapiens

<220>
<221> SIGNAL
<222> (1)...(13)

<400> 6
Met Gly Leu Leu Met Leu Trp Val Ser Gly Ser Ser Gly Asp Ile Val
            -10   -5   1
Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala
    5   10   15
Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser Asn Gly Tyr
20   25   30   35
Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu
            40   45   50
Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro Asp Arg Phe
        55   60   65
Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val
        70   75   80
Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala Leu Gln Thr
    85   90   95
Pro Arg Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100   105   110

<210> 7
<211> 100
<212> PRT
<213> Homo sapiens

<400> 7
Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
1   5   10   15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser
        20   25   30
Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser
        35   40   45

4

ELN-002

```
Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro
    50              55                  60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65              70                  75                  80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala
                85                  90                  95
Leu Gln Thr Pro
            100
```

```
<210> 8
<211> 138
<212> PRT
<213> Artificial Sequence

<220>
<223> Humanized 3D6 heavy chain variable region

<221> SIGNAL
<222> (1)...(19)

<400> 8
Met Asn Phe Gly Leu Ser Leu Ile Phe Leu Val Leu Val Leu Lys Gly
                -15                 -10                 -5
Val Gln Cys Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln
            1               5                   10
Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe
    15              20                  25
Ser Asn Tyr Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu
30              35                  40                  45
Glu Trp Val Ala Ser Ile Arg Ser Gly Gly Gly Arg Thr Tyr Tyr Ser
                50                  55                  60
Asp Asn Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn
                65                  70                  75
Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu
        80                  85                  90
Tyr Tyr Cys Val Arg Tyr Asp His Tyr Ser Gly Ser Ser Asp Tyr Trp
    95                  100                 105
Gly Gln Gly Thr Leu Val Thr Val Ser Ser
110             115
```

```
<210> 9
<211> 121
<212> PRT
<213> Homo sapiens

<400> 9
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1               5                   10                  15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
            20                  25                  30
Ala Val Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
            35                  40                  45
Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
    50                  55                  60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
65                  70                  75                  80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys
                85                  90                  95
Ala Lys Asp Asn Tyr Asp Phe Trp Ser Gly Thr Phe Asp Tyr Trp Gly
            100                 105                 110
Gln Gly Thr Leu Val Thr Val Ser Ser
```

5

ELN-002

115 120

```
<210> 10
<211> 98
<212> PRT
<213> Homo sapiens

<400> 10
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1               5                   10                  15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
            20                  25                  30
Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
        35                  40                  45
Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
    50                  55                  60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95
Ala Lys
```

```
<210> 11
<211> 132
<212> PRT
<213> Artificial Sequence

<220>
<221> SIGNAL
<222> (1)...(20)

<223> humanized 3D6 light chain variable region

<400> 11
Met Met Ser Pro Ala Gln Phe Leu Phe Leu Leu Val Leu Trp Ile Arg
-20                 -15                 -10                 -5
Glu Thr Asn Gly Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro
                1                   5                   10
Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser
        15                  20                  25
Leu Leu Asp Ser Asp Gly Lys Thr Tyr Leu Asn Trp Leu Leu Gln Lys
    30                  35                  40
Pro Gly Gln Ser Pro Gln Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp
45                  50                  55                  60
Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe
                65                  70                  75
Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr
                80                  85                  90
Cys Trp Gln Gly Thr His Phe Pro Arg Thr Phe Gly Gln Gly Thr Lys
            95                  100                 105
Val Glu Ile Lys
        110
```

```
<210> 12
<211> 138
<212> PRT
<213> Artificial Sequence

<220>
```

6

ELN-002

<223> Humanized 3D6 light chain variable region

<221> SIGNAL
<222> (1)...(19)

<400> 12
Met Asn Phe Gly Leu Ser Leu Ile Phe Leu Val Leu Val Leu Lys Gly
            -15   -10   -5
Val Gln Cys Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln
            1   5   10
Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe
    15   20   25
Ser Asn Tyr Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu
30   35   40   45
Glu Trp Val Ala Ser Ile Arg Ser Gly Gly Gly Arg Thr Tyr Tyr Ser
            50   55   60
Asp Asn Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn
            65   70   75
Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val
            80   85   90
Tyr Tyr Cys Val Arg Tyr Asp His Tyr Ser Gly Ser Ser Asp Tyr Trp
    95   100   105
Gly Gln Gly Thr Leu Val Thr Val Ser Ser
110   115

<210> 13
<211> 393
<212> DNA
<213> Mus musculus

<220>
<221> CDS
<222> (1)...(393)

<221> sig_peptide
<222> (1)...(57)

<400> 13
atg aag ctg cct gtt agg ctg ttg gta ctg atg ttc tgg att cct gct   48
Met Lys Leu Pro Val Arg Leu Leu Val Leu Met Phe Trp Ile Pro Ala
            -15   -10   -5

tcc agc agt gat gtt ctg atg acc caa act cca ctc tcc ctg cct gtc   96
Ser Ser Ser Asp Val Leu Met Thr Gln Thr Pro Leu Ser Leu Pro Val
            1   5   10

agt ctt gga gat caa gcc tcc atc tct tgc aga tct agt cag aac att   144
Ser Leu Gly Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Asn Ile
    15   20   25

ata cat agt aac gga aac acc tat tta gaa tgg tac ctg cag aaa cca   192
Ile His Ser Asn Gly Asn Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro
30   35   40   45

ggc cag tct cca aag ctc ctg atc tac aaa gtt tcc aac cga ttt tct   240
Gly Gln Ser Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser
            50   55   60

ggg gtc cca gac agg ttc agt ggc agt gga tca ggg aca gat ttc aca   288
Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr
            65   70   75

7

ELN-002

```
ctc aag atc aag aaa gtg gag gct gag gat ctg gga atc tat tac tgc   336
Leu Lys Ile Lys Lys Val Glu Ala Glu Asp Leu Gly Ile Tyr Tyr Cys
            80                  85                  90

ttt caa ggt tca cat gtc ccg ctc acg ttc ggt gct ggg acc aag ctg   384
Phe Gln Gly Ser His Val Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu
        95                 100                 105

gag ctg gaa                                                        393
Glu Leu Glu
110
```

<210> 14
<211> 131
<212> PRT
<213> Mus musculus

<220>
<221> SIGNAL
<222> (1)...(19)

<400> 14
```
Met Lys Leu Pro Val Arg Leu Leu Val Leu Met Phe Trp Ile Pro Ala
                -15                 -10                 -5
Ser Ser Ser Asp Val Leu Met Thr Gln Thr Pro Leu Ser Leu Pro Val
                 1                   5                  10
Ser Leu Gly Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Asn Ile
        15                  20                  25
Ile His Ser Asn Gly Asn Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro
30                  35                  40                  45
Gly Gln Ser Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser
                50                  55                  60
Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr
                65                  70                  75
Leu Lys Ile Lys Lys Val Glu Ala Glu Asp Leu Gly Ile Tyr Tyr Cys
                80                  85                  90
Phe Gln Gly Ser His Val Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu
        95                 100                 105
Glu Leu Glu
110
```

<210> 15
<211> 426
<212> DNA
<213> Mus musculus

<220>
<221> CDS
<222> (1)...(426)

<221> sig_peptide
<222> (1)...(57)

<400> 15
```
atg gac agg ctt act tcc tca ttc ctg ctg ctg att gtc cct gca tat   48
Met Asp Arg Leu Thr Ser Ser Phe Leu Leu Leu Ile Val Pro Ala Tyr
                -15                 -10                 -5

gtc ctg tcc cag gct act ctg aaa gag tct ggc cct gga ata ttg cag   96
Val Leu Ser Gln Ala Thr Leu Lys Glu Ser Gly Pro Gly Ile Leu Gln
                 1                   5                  10
```

8

ELN-002

```
tcc tcc cag acc ctc agt ctg act tgt tct ttc tct ggg ttt tca ctg    144
Ser Ser Gln Thr Leu Ser Leu Thr Cys Ser Phe Ser Gly Phe Ser Leu
    15                  20                  25

agc act tcc ggt atg gga ctg agc tgg att cgt cag cct tca gga aag    192
Ser Thr Ser Gly Met Gly Val Ser Trp Ile Arg Gln Pro Ser Gly Lys
30                  35                  40                  45

ggt ctg gag tgg ctg gca cac att tac tgg gat gat gac aag cgc tat    240
Gly Leu Glu Trp Leu Ala His Ile Tyr Trp Asp Asp Asp Lys Arg Tyr
                50                  55                  60

aac cca tcc ctg aag agc cgg ctc aca atc tcc aag gat acc tcc aga    288
Asn Pro Ser Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Arg
                65                  70                  75

aag cag gta ttc ctc aag atc acc agt gtg gac cct gca gat act gcc    336
Lys Gln Val Phe Leu Lys Ile Thr Ser Val Asp Pro Ala Asp Thr Ala
                80                  85                  90

aca tac tac tgt gtt cga agg ccc att act ccg gta cta gtc gat gct    384
Thr Tyr Tyr Cys Val Arg Arg Pro Ile Thr Pro Val Leu Val Asp Ala
                95                  100                 105

atg gac tac tgg ggt caa gga acc tca gtc acc gtc tcc tca            426
Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser
110                 115                 120
```

<210> 16
<211> 142
<212> PRT
<213> Mus musculus

<220>
<221> SIGNAL
<222> (1)...(19)

```
<400> 16
Met Asp Arg Leu Thr Ser Ser Phe Leu Leu Leu Ile Val Pro Ala Tyr
             -15                 -10                 -5
Val Leu Ser Gln Ala Thr Leu Lys Glu Ser Gly Pro Gly Ile Leu Gln
             1                   5                   10
Ser Ser Gln Thr Leu Ser Leu Thr Cys Ser Phe Ser Gly Phe Ser Leu
    15                  20                  25
Ser Thr Ser Gly Met Gly Val Ser Trp Ile Arg Gln Pro Ser Gly Lys
30                  35                  40                  45
Gly Leu Glu Trp Leu Ala His Ile Tyr Trp Asp Asp Asp Lys Arg Tyr
                50                  55                  60
Asn Pro Ser Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Arg
                65                  70                  75
Lys Gln Val Phe Leu Lys Ile Thr Ser Val Asp Pro Ala Asp Thr Ala
                80                  85                  90
Thr Tyr Tyr Cys Val Arg Arg Pro Ile Thr Pro Val Leu Val Asp Ala
                95                  100                 105
Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser
110                 115                 120
```

<210> 17
<211> 136
<212> DNA

9

ELN-002

<213> Artificial Sequence

<220>
<223> primer

<400> 17
tccgcaagct tgccgccacc atggacatgc gcgtgcccgc ccagctgctg ggcctgctga 60
tgctgtgggt gtccggctcc tccggctacg tggtgatgac ccagtccccc ctgtccctgc 120
ccgtgacccc cggcga   136

<210> 18
<211> 131
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 18
ctggggggac tggccgggct cctgcagcag ccagttcagg taggtcttgc cgtcggagtc 60
cagcagggac tgggaggact tgcaggagat ggaggcgggc cgccggggg tcacgggcag 120
ggacaggggg g   131

<210> 19
<211> 146
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 19
acctgaactg gctgctgcag aagcccggcc agtccccca gcgcctgatc tacctggtgt 60
ccaagctgga ctccggcgtg cccgaccgct tctccggctc cggctccggc accgacttca 120
ccctgaagat ctcccgcgtg gaggcc   146

<210> 20
<211> 142
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 20
aattctagga tccactcacg cttgatctcc accttggtgc cctggccgaa ggtgcggggg 60
aagtgggtgc cctgccagca gtagtacacg cccacgtcct cggcctccac gcgggagatc 120
ttcagggtga agtcggtgcc gg   142

<210> 21
<211> 16
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 21
ctggggggac tggccg   16

<210> 22
<211> 22
<212> DNA

10

ELN-002

<<213> Artificial Sequence

<220>
<223> primer

<400> 22
acctgaactg gctgctgcag aa   22

<210> 23
<211> 138
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 23
acagaaagct tgccgccacc atggagtttg ggctgagctg gcttttctt gtggctattc 60
taaaaggtgt ccagtgtgag gtgcagctgc tggagtccgg cggcggcctg gtgcagcccg 120
gcggctccct cgcctgt   138

<210> 24
<211> 135
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 24
gccgccggag cggatggagg ccacccactc caggcccttg ccgggggcct ggcgcaccca 60
ggacatgccg tagttggaga agctgaagcc ggaggcggcg caggacaggc gcagggagcc 120
gccgggctgc accag   135

<210> 25
<211> 142
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 25
ctggagtggg tggcctccat ccgctccggc ggcggccgca cctactactc cgacaacgtg 60
aagggccgct tcaccatctc ccgcgacaac gccaagaact ccctgtacct gcagatgaac 120
tccctgcgcg ccgaggacac cg   142

<210> 26
<211> 144
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 26
ctgcaaggat ccactcaccg gaggacacgg tcaccagggt gccctggccc cagtagtcgg 60
aggagccgga gtagtggtcg tagcgcacgc agtagtacag ggcggtgtcc tcggcgcgca 120
gggagttcat ctgcaggtac aggg   144

<210> 27
<211> 16
<212> DNA

11

ELN-002

<213> Artificial Sequence

<220>
<223> primer

<400> 27
gccgccggag cggatg   16

<210> 28
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 28
ctggagtggg tggcctccat   20

<210> 29
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 29
tccgcaagct tgccgccac   19

<210> 30
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 30
aattctagga tccactcacg cttgatctc   29

<210> 31
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 31
acagaaagct tgccgccacc atg   23

<210> 32
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 32
ctgcaaggat ccactcaccg ga   22

12

ELN-002

<210> 33
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> native ABeta peptide

<400> 33
Asp Ala Glu Phe Arg His Asp Ser Gly Tyr
 1   5   10

<210> 34
<211> 402
<212> DNA
<213> Artificial Sequence

<220>
<223> h3D6 version 1 VL

<400> 34
atggacatgc gcgtgcccgc ccagctgctg ggcctgctga tgctgtgggt gtccggctcc 60
tccggctacg tggtgatgac ccagtccccc ctgtccctgc ccgtgacccc cggcgagccc 120
gcctccatct cctgcaagtc ctcccagtcc ctgctggact ccgacggcaa gacctacctg 180
aactggctgc tgcagaagcc cggccagtcc ccccagcgcc tgatctacct ggtgtccaag 240
ctggactccg gcgtgcccga ccgcttctcc ggctccggct ccggcaccga cttcaccctg 300
aagatctccc gcgtggaggc cgaggacgtg ggcgtgtact actgctggca gggcacccac 360
ttccccccgca ccttcggcca gggcaccaag gtggagatca ag   402

<210> 35
<211> 402
<212> DNA
<213> Artificial Sequence

<220>
<223> h3D6 version 2 VL

<400> 35
atggacatgc gcgtgcccgc ccagctgctg ggcctgctga tgctgtgggt gtccggctcc 60
tccggcgacg tggtgatgac ccagtccccc ctgtccctgc ccgtgacccc cggcgagccc 120
gcctccatct cctgcaagtc ctcccagtcc ctgctggact ccgacggcaa gacctacctg 180
aactggctgc tgcagaagcc cggccagtcc ccccagcgcc tgatctacct ggtgtccaag 240
ctggactccg gcgtgcccga ccgcttctcc ggctccggct ccggcaccga cttcaccctg 300
aagatctccc gcgtggaggc cgaggacgtg ggcgtgtact actgctggca gggcacccac 360
ttccccccgca ccttcggcca gggcaccaag gtggagatca ag   402

<210> 36
<211> 414
<212> DNA
<213> Artificial Sequence

<220>
<223> h3D6 version 1 VH

<400> 36
atggagtttg ggctgagctg gctttttctt gtggctattt taaaaggtgt ccagtgtgag 60
gtgcagctgc tggagtccgg cggcggcctg gtgcagcccg gcggctccct gcgcctgtcc 120
tgcgccgcct ccggcttcac cttctccaac tacggcatgt cctgggtgcg ccaggccccc 180
ggcaagggcc tggagtgggt ggcctccatc cgctccggcg gcggccgcac ctactactcc 240
gacaacgtga agggccgctt caccatctcc cgcgacaacg ccaagaactc cctgtacctg 300
cagatgaact ccctgcgcgc cgaggacacc gccctgtact actgcgtgcg ctacgaccac 360
tactccggct cctccgacta ctggggccag ggcacccctgg tgaccgtgtc ctcc   414

13

ELN-002

<210> 37
<211> 414
<212> DNA
<213> Artificial Sequence

<220>
<223> h3D6 version 2 VH

<400> 37
atggagtttg ggctgagctg gctttttctt gtggctattt taaaaggtgt ccagtgtgag 60
gtgcagctgc tggagtccgg cggcggcctg gtgcagcccg gcggctcccc gcgcctgtcc 120
tgcgccgcct ccggcttcac cttctccaac tacggcatgt cctgggtgcg ccaggccccc 180
ggcaagggcc tggagtgggt ggcctccatc cgctccggcg gcggccgcac ctactactcc 240
gacaacgtga agggccgctt caccatctcc cgcgacaact ccaagaacac cctgtacctg 300
cagatgaact ccctgcgcgc cgaggacacc gccgtgtact actgcgtgcg ctacgaccac 360
tactccggct cctccgacta ctggggccag ggcaccctgg tgaccgtgtc ctcc   414

<210> 38
<211> 770
<212> PRT
<213> Homo sapiens

<400> 38
Met Leu Pro Gly Leu Ala Leu Leu Leu Ala Ala Trp Thr Ala Arg
1   5   10   15
Ala Leu Glu Val Pro Thr Asp Gly Asn Ala Gly Leu Leu Ala Glu Pro
            20   25   30
Gln Ile Ala Met Phe Cys Gly Arg Leu Asn Met His Met Asn Val Gln
        35   40   45
Asn Gly Lys Trp Asp Ser Asp Pro Ser Gly Thr Lys Thr Cys Ile Asp
    50   55   60
Thr Lys Glu Gly Ile Leu Gln Tyr Cys Gln Glu Val Tyr Pro Glu Leu
65   70   75   80
Gln Ile Thr Asn Val Val Glu Ala Asn Gln Pro Val Thr Ile Gln Asn
                85   90   95
Trp Cys Lys Arg Gly Arg Lys Gln Cys Lys Thr His Pro His Phe Val
            100   105   110
Ile Pro Tyr Arg Cys Leu Val Gly Glu Phe Val Ser Asp Ala Leu Leu
        115   120   125
Val Pro Asp Lys Cys Lys Phe Leu His Gln Glu Arg Met Asp Val Cys
    130   135   140
Glu Thr His Leu His Trp His Thr Val Ala Lys Glu Thr Cys Ser Glu
145   150   155   160
Lys Ser Thr Asn Leu His Asp Tyr Gly Met Leu Leu Pro Cys Gly Ile
                165   170   175
Asp Lys Phe Arg Gly Val Glu Phe Val Cys Cys Pro Leu Ala Glu Glu
            180   185   190
Ser Asp Asn Val Asp Ser Ala Asp Ala Glu Glu Asp Asp Ser Asp Val
            195   200   205
Trp Trp Gly Gly Ala Asp Thr Asp Tyr Ala Asp Gly Ser Glu Asp Lys
    210   215   220
Val Val Glu Val Ala Glu Glu Glu Val Ala Glu Val Glu Glu Glu
225   230   235   240
Glu Ala Asp Asp Asp Glu Asp Asp Glu Asp Gly Asp Glu Val Glu Glu
                245   250   255
Glu Ala Glu Glu Pro Tyr Glu Glu Ala Thr Glu Arg Thr Thr Ser Ile
            260   265   270
Ala Thr Thr Thr Thr Thr Thr Thr Glu Ser Val Glu Glu Val Val Arg
        275   280   285
Glu Val Cys Ser Glu Gln Ala Glu Thr Gly Pro Cys Arg Ala Met Ile
    290   295   300
Ser Arg Trp Tyr Phe Asp Val Thr Glu Gly Lys Cys Ala Pro Phe Phe

14

ELN-002

```
305                      310                      315                      320
Tyr Gly Gly Cys Gly Gly Asn Arg Asn Asn Phe Asp Thr Glu Glu Tyr
                325                      330                      335
Cys Met Ala Val Cys Gly Ser Ala Met Ser Gln Ser Leu Leu Lys Thr
                340                      345                      350
Thr Gln Glu Pro Leu Ala Arg Asp Pro Val Lys Leu Pro Thr Thr Ala
    .   355                      360                      365
Ala Ser Thr Pro Asp Ala Val Asp Lys Tyr Leu Glu Thr Pro Gly Asp
    370                      375                      380
Glu Asn Glu His Ala His Phe Gln Lys Ala Lys Glu Arg Leu Glu Ala
385                      390                      395                      400
Lys His Arg Glu Arg Met Ser Gln Val Met Arg Glu Trp Glu Glu Ala
                405                      410                      415
Glu Arg Gln Ala Lys Asn Leu Pro Lys Ala Asp Lys Lys Ala Val Ile
                420                      425                      430
Gln His Phe Gln Glu Lys Val Glu Ser Leu Glu Gln Glu Ala Ala Asn
                435                      440                      445
Glu Arg Gln Gln Leu Val Glu Thr His Met Ala Arg Val Glu Ala Met
    450                      455                      460
Leu Asn Asp Arg Arg Arg Leu Ala Leu Glu Asn Tyr Ile Thr Ala Leu
465                      470                      475                      480
Gln Ala Val Pro Pro Arg Pro Arg His Val Phe Asn Met Leu Lys Lys
                485                      490                      495
Tyr Val Arg Ala Glu Gln Lys Asp Arg Gln His Thr Leu Lys His Phe
                500                      505                      510
Glu His Val Arg Met Val Asp Pro Lys Lys Ala Ala Gln Ile Arg Ser
    515              .       520                      525
Gln Val Met Thr His Leu Arg Val Ile Tyr Glu Arg Met Asn Gln Ser
    530                      535              .       540
Leu Ser Leu Leu Tyr Asn Val Pro Ala Val Ala Glu Glu Ile Gln Asp
545                      550                      555                      560
Glu Val Asp Glu Leu Leu Gln Lys Glu Gln Asn Tyr Ser Asp Asp Val
                565                      570                      575
Leu Ala Asn Met Ile Ser Glu Pro Arg Ile Ser Tyr Gly Asn Asp Ala
                580                      585                      590
Leu Met Pro Ser Leu Thr Glu Thr Lys Thr Thr Val Glu Leu Leu Pro
    .           595                      600                      605          .
Val Asn Gly Glu Phe Ser Leu Asp Asp Leu Gln Pro Trp His Ser Phe
    610                      615                      620
Gly Ala Asp Ser Val Pro Ala Asn Thr Glu Asn Glu Val Glu Pro Val
625                      630                      635                      640
Asp Ala Arg Pro Ala Ala Asp Arg Gly Leu Thr Thr Arg Pro Gly Ser
                645                      650                      655
Gly Leu Thr Asn Ile Lys Thr Glu Glu Ile Ser Glu Val Lys Met Asp
                660                      665                      670
Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys Leu
    675                      680                      685
Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile Gly
    690                      695                      700
Leu Met Val Gly Gly Val Val Ile Ala Thr Val Ile Val Ile Thr Leu
705                      710                      715                      720
Val Met Leu Lys Lys Lys Gln Tyr Thr Ser Ile His His Gly Val Val
                725                      730                      735
Glu Val Asp Ala Ala Val Thr Pro Glu Glu Arg His Leu Ser Lys Met
                740                      745                      750
Gln Gln Asn Gly Tyr Glu Asn Pro Thr Tyr Lys Phe Phe Glu Gln Met
                755                      760                      765
Gln Asn
    770
```

<210> 39
<211> 40

15

ELN-002

```
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 39
actagtcgac atgaagttgc ctgttaggct gttggtgctg                          40

<210> 40
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 40
actagtcgac atggagwcag acacactcct gytatgggt                           39

<210> 41
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 41
actagtcgac atgagtgtgc tcactcaggt cctggsgttg                          40

<210> 42
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 42
actagtcgac atgaggrccc ctgctcagwt tyttggmwtc ttg                      43

<210> 43
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 43
actagtcgac atggatttwc aggtgcagat twtcagcttc                          40

<210> 44
<211> 37
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 44
actagtcgac atgaggtkcy ytgytsagyt yctgrgg                             37
```

16

PLN-002

<210> 45
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 45
actagtcgac atgggcwtca agatggagtc acakwyycwg g   41

<210> 46
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 46
actagtcgac atgtggggay cckttctycmm tttttcaatt g   41

<210> 47
<211> 35
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 47
actagtcgac atggtrtccw casctcagtt cctrg   35

<210> 48
<211> 37
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 48
actagtcgac atgtatatat gtttgttgtc tattcct   37

<210> 49
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 49
actagtcgac atggaagccc cagctcagct tctcttcc   38

<210> 50
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

17

ELN-002


```
<400> 50
ggatcccggg tggatggtgg gaagatg                                          27

<210> 51
<211> 37
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 51
actagtcgac atgaaatgca gctgggtcat attcttc                               37

<210> 52
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 52
actagtcgac atgggatgga gctrcatcat sytctc                                36

<210> 53
<211> 37
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 53
actagtcgac atgaagwtgt ggttaaactg ggtcttt                               37

<210> 54
<211> 35
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 54
actagtcgac atgractttg ggytcagctt grtct                                 35

<210> 55
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 55
actagtcgac atggactcca ggctcaattt agttttcctt                            40

<210> 56
<211> 37
<212> DNA
<213> Artificial Sequence
```

18

ELN-002

```
<220>
<223> primer

<400> 56
actagtcgac atggctgtcy trysgctrct cttctgc                                37

<210> 57
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 57
actagtcgac atggratgga gctggrcctt tmtctt                                 36

<210> 58
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 58
actagtcgac atgagagtgc tgattcttct gtg                                    33

<210> 59
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 59
actagtcgac atggmttggg tgtggamctt gctattcctg                             40

<210> 60
<211> 37
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 60
actagtcgac atgggcagac ttacattctc attcctg                                37

<210> 61
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 61
actagtcgac atggattttg ggctgatttt ttttattg                               38

<210> 62
```

19

ELN-002

<211> 37
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 62
actagtcgac atgatggtgt caagtcttct gtacctg   37

<210> 63
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 63
ggatcccggg agtggataga ctgatgg   27

20

EXHIBIT 7

PAGE: 1   VERIFICATION SUMMARY REPORT   DATE:
02/23/2007
                               PATENT APPLICATION   TIME:
10:39:24

                               INPUT SEQ: G:\Data\E\ELN\002\Petition for
Reconsideration\Sequence Listing\sequence listing text.txt

GENERAL INFORMATION SECTION

          3,<110> Basi, Guriq
          4,   Saldanha, Jose
          5,   Yednock, Ted
          7,<120> HUMANIZED ANTIBODIES THAT RECOGNIZE
          8,   BETA-AMYLOID PEPTIDE
         10,<130> ELN-002
         12,<140> US 10/010,942
         13,<141> 2001-12-06
         15,<150> US 60/251,892
         16,<151> 2000-12-06
         18,<160> 63
         20,<170> FastSEQ for Windows Version 4.0

ERRORED LINES SECTION

STATISTICS SUMMARY

     Application Serial Number: US 10/010,942
            Alpha or Numeric: Numeric
           Application Class:
         Application File Date: 2001-12-06
                    Art Unit:
        Software Application: FastSEQ
    Total Number of Sequences: 63
            Total Nucleotides: 5470
            Total Amino Acids: 2307
             Number of Errors: 0
           Number of Warnings: 0
         Number of Corrections: 0

EXHIBIT 8

Docket No.: ELN-002
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Guriq Basi *et al.*

Application No.: 10/010942

Confirmation No.: 5594

Filed: December 6, 2001

Art Unit: 1649

For: HUMANIZED ANTIBODIES THAT
RECOGNIZE BETA AMYLOID PEPTIDE

Examiner: Ballard, Kimberly A.

AFFIDAVIT BY MICAELA C. HILL

MS Petition
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

I, Ms. Micaela C. Hill, declare the following:

1. I am presently a paralegal at the firm of Lahive & Cockfield LLP. I have been employed as a paralegal for approximately 1 year. My responsibilities include the preparation of Sequence Listings, including sequence diskettes, for submission to the United States Patent & Trademark Office (USPTO).

2. I have inspected Applicants' Attorney's file copy of the sequence diskette mailed on July 1, 2002 to the USPTO and confirm that it is in working condition and in computer-readable form.

Serial No. 10/010,942   ELN-002

3.   I have used Applicants' Attorney's file copy of the diskette mailed July 1, 2002
to print a paper copy of the Sequence Listing contained thereon. The paper copy of Applicants'
Attorney's file copy of the July 1, 2002 sequence diskette is submitted together with this
Affidavit as Exhibit 6.

4.   I hereby state that the content of Applicants' Attorney's file copy of the July 1,
2002 diskette and the paper copy of the Sequence Listing contained thereon are the same.

5.   I declare further that all statements made herein of my own knowledge are true
and that all statements made on information and belief are believed to be true; and further that
these statements are made with the knowledge that willful false statements and the like so made
are punishable by fine or imprisonment, or both, under §1001 of Title XVIII of the United States
Code, and that such willful false statements may jeopardize the validity of this Application for
Patent or any patent issuing thereon.

Date: February 26, 2007   Signed: _____
                                                          Micaela C. Hill

2

EXHIBIT 9

SeqlistCorrected.txt
SEQUENCE LISTING

<110> Basi, Guriq
      Saldanha, Jose
      Yednock, Ted

<120> HUMANIZED ANTIBODIES THAT RECOGNIZE
      BETA-AMYLOID PEPTIDE

<130> ELN-002

<140> US 10/010,942
<141> 2001-12-06

<150> US 60/251,892
<151> 2000-12-06

<160> 63

<170> FastSEQ for Windows version 4.0

<210> 1
<211> 396
<212> DNA
<213> Mus musculus

<220>
<221> CDS
<222> (1)...(396)

<221> sig_peptide
<222> (1)...(60)

<400> 1
atg atg agt cct gcc cag ttc ctg ttt ctg tta gtg ctc tgg att cgg   48
Met Met Ser Pro Ala Gln Phe Leu Phe Leu Leu Val Leu Trp Ile Arg
            -15   -10   -5
-20

gaa acc aac ggt tat gtt gtg atg acc cag act cca ctc act ttg tcg   96
Glu Thr Asn Gly Tyr Val Val Met Thr Gln Thr Pro Leu Thr Leu Ser
                1   5   10

gtt acc att gga caa cca gcc tcc atc tct tgc aag tca agt cag agc   144
Val Thr Ile Gly Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser
            15   20   25

ctc tta gat agt gat gga aag aca tat ttg aat tgg ttg tta cag agg   192
Leu Leu Asp Ser Asp Gly Lys Thr Tyr Leu Asn Trp Leu Leu Gln Arg
            30   35   40

cca ggc cag tct cca aag cgc cta atc tat ctg gtg tct aaa ctg gac   240
Pro Gly Gln Ser Pro Lys Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp
45   50   55   60

tct gga gtc cct gac agg ttc act ggc agt gga tca ggg aca gat ttt   288
Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe
                65   70   75

aca ctg aaa atc agc aga ata gag gct gag gat ttg gga ctt tat tat   336
Thr Leu Lys Ile Ser Arg Ile Glu Ala Glu Asp Leu Gly Leu Tyr Tyr
            80   85   90

tgc tgg caa ggt aca cat ttt cct cgg acg ttc ggt gga ggc acc aag   384
                                        Page 1

EXHIBIT 10

~~Docket No.: ELN-002~~
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Guriq Basi et al.

Application No.: 10/010942

Filed: December 6, 2001

For: HUMANIZED ANTIBODIES THAT RECOGNIZE BETA AMYLOID PEPTIDE

Confirmation No.: 5594

Art Unit: 1649

Examiner: Ballard, Kimberly A.

AFFIDAVIT BY PATRICIA ROBINSON

MS Petition
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

I, Ms. Patricia Robinson, declare the following:

1.   I am Associate Director of Intellectual Property at Elan Pharmaceuticals, Inc.[1].

2.   At our instruction, Applicants' Attorney sends us duplicate copies of all correspondence filed with the USPTO, including sequence diskettes. I have inspected our file copy of the sequence diskette mailed by Applicants' Attorney on July 1, 2002 to the USPTO and confirm that it is in working condition and in computer-readable form.

---

[1] Elan Pharmaceuticals, Inc. is a wholly-owned subsidiary of Elan Corporation, plc. Elan Pharma International Ltd., a co-assignee of record in the above-referenced application, is an indirect wholly-owned subsidiary of Elan Corporation, plc

ELN-002

Serial No. 10/010,942

3.   I have used our file copy of the diskette mailed by Applicants' Attorney's on July 1, 2002 to print a paper copy of the Sequence Listing contained thereon. The paper copy of our file copy of the July 1, 2002 sequence diskette is submitted together with this Affidavit as Exhibit 9.

4.   I hereby state that the content of our file copy of the July 1, 2002 diskette and the paper copy of the Sequence Listing contained thereon are the same.

5.   I declare further that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under §1001 of Title XVIII of the United States Code, and that such willful false statements may jeopardize the validity of this Application for Patent or any patent issuing thereon.

Date: February 26, 2007   Signed:

-2-

seqlistCorrected.txt

```
           Cys Trp Gln Gly Thr His Phe Pro Arg Thr Phe Gly Gly Gly Thr Lys
                       95              100             105

                                                                    396
ctg gaa atc aaa
Leu Glu Ile Lys
        110


<210> 2
<211> 132
<212> PRT
<213> Mus musculus

<220>
<221> SIGNAL
<222> (1)...(20)

<400> 2
Met Met Ser Pro Ala Gln Phe Leu Phe Leu Leu Val Leu Trp Ile Arg
-20          -15                      -10                      -5
Glu Thr Asn Gly Tyr Val Val Met Thr Gln Thr Pro Leu Thr Leu Ser
              1                   5                   10
Val Thr Ile Gly Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser
          15                  20                  25
Leu Leu Asp Ser Asp Gly Lys Thr Tyr Leu Asn Trp Leu Leu Gln Arg
      30                  35                  40
Pro Gly Gln Ser Pro Lys Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp
  45                  50                  55                  60
Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe
                  65                  70                  75
Thr Leu Lys Ile Ser Arg Ile Glu Ala Glu Asp Leu Gly Leu Tyr Tyr
              80                  85                  90
Cys Trp Gln Gly Thr His Phe Pro Arg Thr Phe Gly Gly Gly Thr Lys
          95                  100             105
Leu Glu Ile Lys
        110


<210> 3
<211> 414
<212> DNA
<213> Mus musculus

<220>
<221> CDS
<222> (1)...(414)

<221> sig_peptide
<222> (1)...(57)

<400> 3
atg aac ttc ggg ctc agc ttg att ttc ctt gtc ctt gtt tta aaa ggt    48
Met Asn Phe Gly Leu Ser Leu Ile Phe Leu Val Leu Val Leu Lys Gly
        -15                 -10                         -5
gtc cag tgt gaa gtg aag ctg gtg gag tct ggg gga ggc tta gtg aag    96
Val Gln Cys Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Lys
          1                   5                   10
cct gga gcg tct ctg aaa ctc tcc tgt gca gcc tct gga ttc act ttc   144
Pro Gly Ala Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe
          15                  20                  25
```

Page 2

SeqlistCorrected.txt

```
agt aac tat ggc atg tct tgg gtt cgc cag aat tca gac aag agg ctg   192
Ser Asn Tyr Gly Met Ser Trp Val Arg Gln Asn Ser Asp Lys Arg Leu
30              35                  40                  45

gag tgg gtt gca tcc att agg agt ggt ggt ggt aga acc tac tat tca   240
Glu Trp Val Ala Ser Ile Arg Ser Gly Gly Gly Arg Thr Tyr Tyr Ser
                50                  55                  60

gac aat gta aag ggc cga ttc acc atc tcc aga gag aat gcc aag aac   288
Asp Asn Val Lys Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn
            65                  70                  75

acc ctg tac ctg caa atg agt agt ctg aag tct gag gac acg gcc ttg   336
Thr Leu Tyr Leu Gln Met Ser Ser Leu Lys Ser Glu Asp Thr Ala Leu
        80                  85                  90

tat tat tgt gtc aga tat gat cac tat agt ggt agc tcc gac tac tgg   384
Tyr Tyr Cys Val Arg Tyr Asp His Tyr Ser Gly Ser Ser Asp Tyr Trp
    95                  100                 105

                                                                  414
ggc cag ggc acc act gtc aca gtc tcc tca
Gly Gln Gly Thr Thr Val Thr Val Ser Ser
110             115
```

<210> 4
<211> 138
<212> PRT
<213> Mus musculus

<220>
<221> SIGNAL
<222> (1)...(19)

```
<400> 4
Met Asn Phe Gly Leu Ser Leu Ile Phe Leu Val Leu Val Leu Lys Gly
                -15                 -10                     -5
Val Gln Cys Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Lys
            1               5                   10
Pro Gly Ala Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe
    15                  20                  25
Ser Asn Tyr Gly Met Ser Trp Val Arg Gln Asn Ser Asp Lys Arg Leu
30              35                  40                  45
Glu Trp Val Ala Ser Ile Arg Ser Gly Gly Gly Arg Thr Tyr Tyr Ser
                50                  55                  60
Asp Asn Val Lys Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn
            65                  70                  75
Thr Leu Tyr Leu Gln Met Ser Ser Leu Lys Ser Glu Asp Thr Ala Leu
        80                  85                  90
Tyr Tyr Cys Val Arg Tyr Asp His Tyr Ser Gly Ser Ser Asp Tyr Trp
    95                  100                 105
Gly Gln Gly Thr Thr Val Thr Val Ser Ser
110             115
```

<210> 5
<211> 132
<212> PRT
<213> Artificial sequence

<220>
<221> SIGNAL
<222> (1)...(20)

Page 3

seqlistcorrected.txt

<223> humanized 3b6 light chain variable region

<400> 5
Met Met Ser Pro Ala Gln Phe Leu Phe Leu Leu Val Leu Trp Ile Arg
              -15   -10   -5
-20
Glu Thr Asn Gly Tyr Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro
                1   5   10
Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser
        15   20   25
Leu Leu Asp Ser Asp Gly Lys Thr Tyr Leu Asn Trp Leu Leu Gln Lys
        30   35   40
Pro Gly Gln Ser Pro Gln Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp
45   50   55   60
Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe
                65   70   75
Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr
            80   85   90
Cys Trp Gln Gly Thr His Phe Pro Arg Thr Phe Gly Gln Gly Thr Lys
        95   100   105
Val Glu Ile Lys
    110

<210> 6
<211> 125
<212> PRT
<213> Homo sapiens

<220>
<221> SIGNAL
<222> (1)...(13)

<400> 6
Met Gly Leu Leu Met Leu Trp Val Ser Gly Ser Ser Gly Asp Ile Val
              -10   -5   1
Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala
5   10   15
Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser Asn Gly Tyr
20   25   30   35
Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu
            40   45   50
Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro Asp Arg Phe
        55   60   65
Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val
    70   75   80
Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala Leu Gln Thr
    85   90   95
Pro Arg Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100   105   110

<210> 7
<211> 100
<212> PRT
<213> Homo sapiens

<400> 7
Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
1   5   10   15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser
        20   25   30
Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser
        35   40   45

Page 4

seqlistCorrected.txt

```
Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro
        50              55                  60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65              70                  75                  80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala
                85              90                  95
Leu Gln Thr Pro
            100
```

<210> 8
<211> 138
<212> PRT
<213> Artificial Sequence

<220>
<223> Humanized 3D6 heavy chain variable region

<221> SIGNAL
<222> (1)...(19)

<400> 8
```
Met Asn Phe Gly Leu Ser Leu Ile Phe Leu Val Leu Val Leu Lys Gly
            -15              -10                      -5
Val Gln Cys Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln
            1                5                    10
Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe
    15              20                  25
Ser Asn Tyr Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu
30              35                  40                  45
Glu Trp Val Ala Ser Ile Arg Ser Gly Gly Gly Arg Thr Tyr Tyr Ser
                50                  55                  60
Asp Asn Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn
            65                  70                  75
Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu
        80                  85                  90
Tyr Tyr Cys Val Arg Tyr Asp His Tyr Ser Gly Ser Ser Asp Tyr Trp
    95                  100                 105
Gly Gln Gly Thr Leu Val Thr Val Ser Ser
110                 115
```

<210> 9
<211> 121
<212> PRT
<213> Homo sapiens

<400> 9
```
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1                5                    10                  15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
        20                  25                  30
Ala Val Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
        35                  40                  45
Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
        50                  55                  60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
65                  70                  75                  80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys
            85                  90                  95
Ala Lys Asp Asn Tyr Asp Phe Trp Ser Gly Thr Phe Asp Tyr Trp Gly
            100                 105                 110
Gln Gly Thr Leu Val Thr Val Ser Ser
```
                                            Page 5

SeqlistCorrected.txt

115 120

<210> 10
<211> 98
<212> PRT
<213> Homo sapiens

<400> 10
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1   5   10   15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
            20   25   30
Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
        35   40   45
Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
    50   55   60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65   70   75   80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85   90   95
Ala Lys

<210> 11
<211> 132
<212> PRT
<213> Artificial Sequence

<220>
<221> SIGNAL
<222> (1)...(20)

<223> humanized 3D6 light chain variable region

<400> 11
Met Met Ser Pro Ala Gln Phe Leu Phe Leu Leu Val Leu Trp Ile Arg
-20   -15   -10   -5
Glu Thr Asn Gly Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro
                1   5   10
Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser
        15   20   25
Leu Leu Asp Ser Asp Gly Lys Thr Tyr Leu Asn Trp Leu Leu Gln Lys
    30   35   40
Pro Gly Gln Ser Pro Gln Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp
45   50   55   60
Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe
                65   70   75
Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr
            80   85   90
Cys Trp Gln Gly Thr His Phe Pro Arg Thr Phe Gly Gln Gly Thr Lys
        95   100   105
Val Glu Ile Lys
    110

<210> 12
<211> 138
<212> PRT
<213> Artificial Sequence

<220>

Page 6

seqlistcorrected.txt

<223> Humanized 3D6 light chain variable region

<221> SIGNAL
<222> (1)...(19)

<400> 12
Met Asn Phe Gly Leu Ser Leu Ile Phe Leu Val Leu Val Leu Lys Gly
          -15   -10   -5
Val Gln Cys Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln
            1   5   10
Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe
      15   20   25
Ser Asn Tyr Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu
  30   35   40   45
Glu Trp Val Ala Ser Ile Arg Ser Gly Gly Gly Arg Thr Tyr Tyr Ser
              50   55   60
Asp Asn Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn
          65   70   75
Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val
      80   85   90
Tyr Tyr Cys Val Arg Tyr Asp His Tyr Ser Gly Ser Ser Asp Tyr Trp
  95   100   105
Gly Gln Gly Thr Leu Val Thr Val Ser Ser
110   115

<210> 13
<211> 393
<212> DNA
<213> Mus musculus

<220>
<221> CDS
<222> (1)...(393)

<221> sig_peptide
<222> (1)...(57)

<400> 13
atg aag ttg cct gtt agg ctg ttg gta ctg atg ttc tgg att cct gct   48
Met Lys Leu Pro Val Arg Leu Leu Val Leu Met Phe Trp Ile Pro Ala
              -15   -10   -5

tcc agc agt gat gtt ttg atg acc caa act cca ctc tcc ctg cct gtc   96
Ser Ser Ser Asp Val Leu Met Thr Gln Thr Pro Leu Ser Leu Pro Val
          1   5   10

agt ctt gga gat caa gcc tcc atc tct tgc aga tct agt cag aac att   144
Ser Leu Gly Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Asn Ile
      15   20   25

ata cat agt aat gga aac acc tat tta gaa tgg tac ctg cag aaa cca   192
Ile His Ser Asn Gly Asn Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro
  30   35   40   45

ggc cag tct cca aag ctc ctg atc tac aaa gtt tcc aac cga ttt tct   240
Gly Gln Ser Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser
              50   55   60

ggg gtc cca gac agg ttc agt ggc agt gga tca ggg aca gat ttc aca   288
Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr
          65   70   75

Page 7

SeqlistCorrected.txt

```
ctc aag atc aag aaa gtg gag gct gag gat ctg gga att tat tac tgc    336
Leu Lys Ile Lys Lys Val Glu Ala Glu Asp Leu Gly Ile Tyr Tyr Cys
              80              85              90

ttt caa ggt tca cat gtt ccg ctc acg ttc ggt gct ggg acc aag ctg    384
Phe Gln Gly Ser His Val Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu
         95             100             105
                                                                   393
gag ctg gaa
Glu Leu Glu
110
```

```
<210> 14
<211> 131
<212> PRT
<213> Mus musculus

<220>
<221> SIGNAL
<222> (1)...(19)

<400> 14
Met Lys Leu Pro Val Arg Leu Leu Val Leu Met Phe Trp Ile Pro Ala
                -15             -10             -5
Ser Ser Ser Asp Val Leu Met Thr Gln Thr Pro Leu Ser Leu Pro Val
        1               5               10
Ser Leu Gly Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Asn Ile
         15             20             25
Ile His Ser Asn Gly Asn Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro
 30             35             40             45
Gly Gln Ser Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser
            50             55             60
Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr
            65             70             75
Leu Lys Ile Lys Lys Val Glu Ala Glu Asp Leu Gly Ile Tyr Tyr Cys
         80             85             90
Phe Gln Gly Ser His Val Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu
         95            100             105
Glu Leu Glu
110
```

```
<210> 15
<211> 426
<212> DNA
<213> Mus musculus

<220>
<221> CDS
<222> (1)...(426)

<221> sig_peptide
<222> (1)...(57)

<400> 15
atg gac agg ctt act tcc tca ttc ctg ctg ctg att gtc cct gca tat    48
Met Asp Arg Leu Thr Ser Ser Phe Leu Leu Leu Ile Val Pro Ala Tyr
        -15             -10                    -5
gtc ctg tcc cag gct act ctg aaa gag tct ggc cct gga ata ttg cag    96
Val Leu Ser Gln Ala Thr Leu Lys Glu Ser Gly Pro Gly Ile Leu Gln
        1               5                   10
```

Page 8

SeqlistCorrected.txt

```
tcc tcc cag acc ctc agt ctg act tgt tct ttc tct ggg ttt tca ctg   144
Ser Ser Gln Thr Leu Ser Leu Thr Cys Ser Phe Ser Gly Phe Ser Leu
        15              20              25

agc act tct ggt atg gga gtg agc tgg att cgt cag cct tca gga aag   192
Ser Thr Ser Gly Met Gly Val Ser Trp Ile Arg Gln Pro Ser Gly Lys
30              35              40              45

ggt ctg gag tgg ctg gca cac att tac tgg gat gat gac aag cgc tat   240
Gly Leu Glu Trp Leu Ala His Ile Tyr Trp Asp Asp Asp Lys Arg Tyr
            50              55              60

aac cca tcc ctg aag agc cgg ctc aca atc tcc aag gat acc tcc aga   288
Asn Pro Ser Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Arg
            65              70              75

aag cag gta ttc ctc aag atc acc agt gtg gac cct gca gat act gcc   336
Lys Gln Val Phe Leu Lys Ile Thr Ser Val Asp Pro Ala Asp Thr Ala
            80              85              90

aca tac tac tgt gtt cga agg ccc att act ccg gta cta gtc gat gct   384
Thr Tyr Tyr Cys Val Arg Arg Pro Ile Thr Pro Val Leu Val Asp Ala
        95              100             105

atg gac tac tgg ggt caa gga acc tca gtc acc gtc tcc tca           426
Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser
110             115             120
```

<210> 16
<211> 142
<212> PRT
<213> Mus musculus

<220>
<221> SIGNAL
<222> (1)...(19)

<400> 16
```
Met Asp Arg Leu Thr Ser Ser Phe Leu Leu Leu Ile Val Pro Ala Tyr
            -15             -10             -5
Val Leu Ser Gln Ala Thr Leu Lys Glu Ser Gly Pro Gly Ile Leu Gln
        1               5               10
Ser Ser Gln Thr Leu Ser Leu Thr Cys Ser Phe Ser Gly Phe Ser Leu
    15              20              25
Ser Thr Ser Gly Met Gly Val Ser Trp Ile Arg Gln Pro Ser Gly Lys
30              35              40              45
Gly Leu Glu Trp Leu Ala His Ile Tyr Trp Asp Asp Asp Lys Arg Tyr
            50              55              60
Asn Pro Ser Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Arg
            65              70              75
Lys Gln Val Phe Leu Lys Ile Thr Ser Val Asp Pro Ala Asp Thr Ala
            80              85              90
Thr Tyr Tyr Cys Val Arg Arg Pro Ile Thr Pro Val Leu Val Asp Ala
        95              100             105
Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser
110             115             120
```

<210> 17
<211> 136
<212> DNA

Page 9

SeqlistCorrected.txt

<213> Artificial Sequence

<220>
<223> primer

<400> 17
tccgcaagct tgccgccacc atggacatgc gcgtgcccgc ccagctgctg ggcctgctga 60
tgctgtgggt gtccggctcc tccggctacg tggtgatgac ccagtccccc ctgtccctgc 120
ccgtgacccc cggcga   136

<210> 18
<211> 131
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 18
ctgggggggac tggccgggct tctgcagcag ccagttcagg taggtcttgc cgtcggagtc 60
cagcagggac tgggaggact tgcaggagat ggaggcgggc tcgccggggg tcacgggcag 120
ggacagggg g   131

<210> 19
<211> 146
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 19
acctgaactg gctgctgcag aagcccggcc agtcccccca gcgcctgatc tacctggtgt 60
ccaagctgga ctccggcgtg cccgaccgct tctccggctc cggctccggc accgacttca 120
ccctgaagat ctcccgcgtg gaggcc   146

<210> 20
<211> 142
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 20
aattctagga tccactcacg cttgatctcc accttggtgc cctggccgaa ggtgcggggg 60
aagtggggtgc cctgccagca gtagtacacg cccacgtcct cggcctccac gcgggagatc 120
ttcagggtga agtcggtgcc 99   142

<210> 21
<211> 16
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 21   16
ctggggggac tggccg

<210> 22
<211> 22
<212> DNA

Page 10

SeqlistCorrected.txt

<<213> Artificial Sequence

<220>
<223> primer

<400> 22   22
acctgaactg gctgctgcag aa

<210> 23
<211> 138
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 23
acagaaagct tgccgccacc atggagtttg ggctgagctg gctttttctt gtggctattt 60
taaaaggtgt ccagtgtgag gtgcagctgc tggagtccgg cggcggcctg gtgcagcccg 120
gcggctccct cgcctgt   138

<210> 24
<211> 135
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 24
gccgccggag cggatggagg ccacccactc caggcccttg ccggggggcct ggcgcaccca 60
ggacatgccg tagttggaga aggtgaagcc ggaggcggcg caggacaggc gcagggagcc 120
gccgggctgc accag   135

<210> 25
<211> 142
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 25
ctggagtggg tggcctcgat ccgctccggc ggcggccgca cctactactc cgacaacgtg 60
aagggccgct tcaccatctc ccgcgacaac gccaagaact ccctgtacct gcagatgaac 120
tccctgcgcg ccgaggacac cg   142

<210> 26
<211> 144
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 26
ctgcaaggat ccactcaccg gaggacacgg tcaccagggt gccctggccc cagtagtcgg 60
aggagccgga gtagtggtcg tagcgcacgc agtagtacag ggcggtgtcc tcggcgcgca 120
gggagttcat ctgcaggtac aggg   144

<210> 27
<211> 16
<212> DNA

Page 11

SeqlistCorrected.txt

<213> Artificial Sequence

<220>
<223> primer

<400> 27   16
gccgccggag cggatg

<210> 28
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 28   20
ctggagtggg tggcctccat

<210> 29
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 29   19
tccgcaagct tgccgccac

<210> 30
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 30   29
aattctagga tccactcacg cttgatctc

<210> 31
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 31   23
acagaaagct tgccgccacc atg

<210> 32
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 32   22
ctgcaaggat ccactcaccg ga

Page 12

SeqlistCorrected.txt

<210> 33
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> native ABeta peptide

<400> 33
Asp Ala Glu Phe Arg His Asp Ser Gly Tyr
1   5   10

<210> 34
<211> 402
<212> DNA
<213> Artificial Sequence

<220>
<223> h3D6 version 1 VL

<400> 34
atggacatgc gcgtgcccgc ccagctgctg ggcctgctga tgctgtgggt gtccggctcc 60
tccggctacg tggtgatgac ccagtccccc ctgtccctgc ccgtgacccc cggcgagccc 120
gcctccatct cctgcaagtc ctcccagtcc ctgctggact ccgacggcaa gacctacctg 180
aactggctgc tgcagaagcc cggccagtcc ccccagcgcc tgatctacct ggtgtccaag 240
ctggactccg gcgtgcccga ccgcttctcc ggctccggct ccggcaccga cttcaccctg 300
aagatctccc gcgtggaggc cgaggacgtg ggcgtgtact actgctggca gggcacccac 360
ttccccgca ccttcggcca gggcaccaag gtggagatca ag 402

<210> 35
<211> 402
<212> DNA
<213> Artificial Sequence

<220>
<223> h3D6 version 2 VL

<400> 35
atggacatgc gcgtgcccgc ccagctgctg ggcctgctga tgctgtgggt gtccggctcc 60
tccggcgacg tggtgatgac ccagtccccc ctgtccctgc ccgtgacccc cggcgagccc 120
gcctccatct cctgcaagtc ctcccagtcc ctgctggact ccgacggcaa gacctacctg 180
aactggctgc tgcagaagcc cggccagtcc ccccagcgcc tgatctacct ggtgtccaag 240
ctggactccg gcgtgcccga ccgcttctcc ggctccggct ccggcaccga cttcaccctg 300
aagatctccc gcgtggaggc cgaggacgtg ggcgtgtact actgctggca gggcacccac 360
ttccccgca ccttcggcca gggcaccaag gtggagatca ag 402

<210> 36
<211> 414
<212> DNA
<213> Artificial Sequence

<220>
<223> h3D6 version 1 VH

<400> 36
atggagtttg ggctgagctg gctttttctt gtggctattt taaaaggtgt ccagtgtgag 60
gtgcagctgc tggagtccgg cggcggcctg gtgcagcccg gcggctccct gcgcctgtcc 120
tgcgccgcct ccggcttcac cttctccaac tacggcatgt cctgggtgcg ccaggccccc 180
ggcaagggcc tggagtgggt ggcctccatc cgctccggcg gcggccgcac ctactactcc 240
gacaacgtga agggccgctt caccatctcc cgcgacaacg ccaagaactc cctgtacctg 300
cagatgaact ccctgcgcgc cgaggacacc gccctgtact actgcgtgcg ctacgaccac 360
tactccggct cctccgacta ctggggccag ggcaccctgg tgaccgtgtc ctcc 414
Page 13

SeqlistCorrected.txt

<210> 37
<211> 414
<212> DNA
<213> Artificial Sequence

<220>
<223> h3D6 version 2 VH

<400> 37
atggagtttg ggctgagctg gctttttctt gtggctattt taaaaggtgt ccagtgtgag 60
gtgcagctgc tggagtccgg cggcggcctg gtgcagcccg gcggctccct gcgcctgtcc 120
tgcgccgcct ccggcttcac cttctccaac tacggcatgt cctgggtgcg ccaggccccc 180
ggcaagggcc tggagtgggt ggcctccatc cgctccggcg gcggccgcac ctactactcc 240
gacaacgtga agggccgctt caccatctcc cgcgacaact ccaagaacac cctgtacctg 300
cagatgaact ccctgcgcgc cgaggacacc gccgtgtact actgcgtgcg ctacgaccac 360
tactccggct cctccgacta ctggggccag ggcaccctgg tgaccgtgtc ctcc   414

<210> 38
<211> 770
<212> PRT
<213> Homo sapiens

<400> 38
Met Leu Pro Gly Leu Ala Leu Leu Leu Leu Ala Ala Trp Thr Ala Arg
1   5   10   15
Ala Leu Glu Val Pro Thr Asp Gly Asn Ala Gly Leu Leu Ala Glu Pro
                20   25   30
Gln Ile Ala Met Phe Cys Gly Arg Leu Asn Met His Met Asn Val Gln
            35   40   45
Asn Gly Lys Trp Asp Ser Asp Pro Ser Gly Thr Lys Thr Cys Ile Asp
        50   55   60
Thr Lys Glu Gly Ile Leu Gln Tyr Cys Gln Glu Val Tyr Pro Glu Leu
65   70   75   80
Gln Ile Thr Asn Val Val Glu Ala Asn Gln Pro Val Thr Ile Gln Asn
                85   90   95
Trp Cys Lys Arg Gly Arg Lys Gln Cys Lys Thr His Pro His Phe Val
            100   105   110
Ile Pro Tyr Arg Cys Leu Val Gly Glu Phe Val Ser Asp Ala Leu Leu
        115   120   125
Val Pro Asp Lys Cys Lys Phe Leu His Gln Glu Arg Met Asp Val Cys
    130   135   140
Glu Thr His Leu His Trp His Thr Val Ala Lys Glu Thr Cys Ser Glu
145   150   155   160
Lys Ser Thr Asn Leu His Asp Tyr Gly Met Leu Leu Pro Cys Gly Ile
                165   170   175
Asp Lys Phe Arg Gly Val Glu Phe Val Cys Cys Pro Leu Ala Glu Glu
            180   185   190
Ser Asp Asn Val Asp Ser Ala Asp Ala Glu Glu Asp Asp Ser Asp Val
        195   200   205
Trp Trp Gly Gly Ala Asp Thr Asp Tyr Ala Asp Gly Ser Glu Asp Lys
    210   215   220
Val Val Glu Val Ala Glu Glu Val Ala Glu Val Glu Glu Glu
225   230   235   240
Glu Ala Asp Asp Asp Glu Asp Asp Glu Asp Gly Asp Glu Val Glu Glu
                245   250   255
Glu Ala Glu Glu Pro Tyr Glu Glu Ala Thr Glu Arg Thr Thr Ser Ile
            260   265   270
Ala Thr Thr Thr Thr Thr Thr Thr Glu Ser Val Glu Glu Val Val Arg
        275   280   285
Glu Val Cys Ser Glu Gln Ala Glu Thr Gly Pro Cys Arg Ala Met Ile
    290   295   300
Ser Arg Trp Tyr Phe Asp Val Thr Glu Gly Lys Cys Ala Pro Phe Phe
                                Page 14

```
                              SeqlistCorrected.txt
   305                  310                  315                  320
 _____

  Tyr Gly Gly Cys Gly Gly Asn Arg Asn Asn Phe Asp Thr Glu Glu Tyr
                325                     330                     335
  Cys Met Ala Val Cys Gly Ser Ala Met Ser Gln Ser Leu Leu Lys Thr
                340                     345                     350
  Thr Gln Glu Pro Leu Ala Arg Asp Pro Val Lys Leu Pro Thr Thr Ala
          355                     360                     365
  Ala Ser Thr Pro Asp Ala Val Asp Lys Tyr Leu Glu Thr Pro Gly Asp
          370                     375                     380
  Glu Asn Glu His Ala His Phe Gln Lys Ala Lys Glu Arg Leu Glu Ala
  385                     390                     395                     400
  Lys His Arg Glu Arg Met Ser Gln Val Met Arg Glu Trp Glu Glu Ala
                    405                     410                     415
  Glu Arg Gln Ala Lys Asn Leu Pro Lys Ala Asp Lys Lys Ala Val Ile
                420                     425                     430
  Gln His Phe Gln Glu Lys Val Glu Ser Leu Glu Gln Glu Ala Ala Asn
              435                     440                     445
  Glu Arg Gln Gln Leu Val Glu Thr His Met Ala Arg Val Glu Ala Met
      450                     455                     460
  Leu Asn Asp Arg Arg Arg Leu Ala Leu Glu Asn Tyr Ile Thr Ala Leu
  465                     470                     475                     480
  Gln Ala Val Pro Pro Arg Pro Arg His Val Phe Asn Met Leu Lys Lys
                  485                     490                     495
  Tyr Val Arg Ala Glu Gln Lys Asp Arg Gln His Thr Leu Lys His Phe
              500                     505                     510
  Glu His Val Arg Met Val Asp Pro Lys Lys Ala Ala Gln Ile Arg Ser
          515                     520                     525
  Gln Val Met Thr His Leu Arg Val Ile Tyr Glu Arg Met Asn Gln Ser
      530                     535                     540
  Leu Ser Leu Leu Tyr Asn Val Pro Ala Val Ala Glu Glu Ile Gln Asp
  545                     550                     555                     560
  Glu Val Asp Glu Leu Leu Gln Lys Glu Gln Asn Tyr Ser Asp Asp Val
                  565                     570                     575
  Leu Ala Asn Met Ile Ser Glu Pro Arg Ile Ser Tyr Gly Asn Asp Ala
              580                     585                     590
  Leu Met Pro Ser Leu Thr Glu Thr Lys Thr Thr Val Glu Leu Leu Pro
          595                     600                     605
  Val Asn Gly Glu Phe Ser Leu Asp Asp Leu Gln Pro Trp His Ser Phe
      610                     615                     620
  Gly Ala Asp Ser Val Pro Ala Asn Thr Glu Asn Glu Val Glu Pro Val
  625                     630                     635                     640
  Asp Ala Arg Pro Ala Ala Asp Arg Gly Leu Thr Thr Arg Pro Gly Ser
                  645                     650                     655
  Gly Leu Thr Asn Ile Lys Thr Glu Glu Ile Ser Glu Val Lys Met Asp
              660                     665                     670
  Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys Leu
          675                     680                     685
  Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile Gly
      690                     695                     700
  Leu Met Val Gly Gly Val Val Ile Ala Thr Val Ile Val Ile Thr Leu
  705                     710                     715                     720
  Val Met Leu Lys Lys Lys Gln Tyr Thr Ser Ile His His Gly Val Val
                  725                     730                     735
  Glu Val Asp Ala Ala Val Thr Pro Glu Glu Arg His Leu Ser Lys Met
              740                     745                     750
  Gln Gln Asn Gly Tyr Glu Asn Pro Thr Tyr Lys Phe Phe Glu Gln Met
          755                     760                     765
  Gln Asn
      770
```

<210> 39
<211> 40

Page 15

SeqlistCorrected.txt

```
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 39
actagtcgac atgaagttgc ctgttaggct gttggtgctg                    40

<210> 40
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 40
actagtcgac atggagwcag acacactcct gytatgggt                     39

<210> 41
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 41
actagtcgac atgagtgtgc tcactcaggt cctggsgttg                    40

<210> 42
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 42
actagtcgac atgaggrccc ctgctcagwt tyttggmwtc ttg                43

<210> 43
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 43
actagtcgac atggatttwc aggtgcagat twtcagcttc                    40

<210> 44
<211> 37
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 44
actagtcgac atgaggtkcy ytgytsagyt yctgrgg                       37
```

Page 16

SeqlistCorrected.txt

```
<210> 45
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 45
actagtcgac atgggcwtca agatggagtc acakwyycwg g                              41

<210> 46
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 46
actagtcgac atgtggggay ctktttycmm ttttccaatt g                              41

<210> 47
<211> 35
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 47
actagtcgac atggtrtccw casctcagtt ccttg                                     35

<210> 48
<211> 37
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 48
actagtcgac atgtatatat gtttgttgtc tatttct                                   37

<210> 49
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 49
actagtcgac atggaagccc cagctcagct tctcttcc                                  38

<210> 50
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> primer
```

Page 17

SeqlistCorrected.txt

<400> 50
ggatcccggg tggatggtgg gaagatg   27

<210> 51
<211> 37
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 51
actagtcgac atgaaatgca gctgggtcat sttcttc   37

<210> 52
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 52
actagtcgac atgggatgga gctttatcat sytctt   36

<210> 53
<211> 37
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 53
actagtcgac atgaagwtgt ggttaaactg ggttttt   37

<210> 54
<211> 35
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 54
actagtcgac atgractttg ggytcagctt grttt   35

<210> 55
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 55
actagtcgac atggactcca ggctcaattt agttttcctt   40

<210> 56
<211> 37
<212> DNA
<213> Artificial Sequence

                              Page 18

SeqlistCorrected.txt

<220>
<223> primer

<400> 56
actagtcgac atggctgtcy trgsgctrct cttctgc   37

<210> 57
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 57
actagtcgac atggratgga gckggrtctt tmtctt   36

<210> 58
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 58
actagtcgac atgagagtgc tgattctttt gtg   33

<210> 59
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 59
actagtcgac atggmttggg tgtggamctt gctattcctg   40

<210> 60
<211> 37
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 60
actagtcgac atgggcagac ttacattctc attcctg   37

<210> 61
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 61
actagtcgac atggattttg ggctgatttt ttttattg   38

<210> 62

Page 19

SeqlistCorrected.txt

```
<211> 37
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 62
actagtcgac atgatggtgt taagtcttct gtacctg                                   37

<210> 63
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 63
ggatcccggg agtggataga ctgatgg                                              27
```

Page 20

EXHIBIT 11

Docket No.: ELN-002
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Guriq Basi *et al.*;

Application No.: 10/010942

Filed: December 6, 2001

For: HUMANIZED ANTIBODIES THAT
    RECOGNIZE BETA AMYLOID PEPTIDE

Confirmation No.: 5594

Art Unit: 1649

Examiner: Ballard, Kimberly A.

AFFIDAVIT BY DEBRA J. MILASINCIC

MS Petition
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

I, Debra J. Milasincic, Esq., declare the following:

1.   I am presently a Partner at the firm of Lahive & Cockfield LLP.

2.   I reviewed and filed on behalf of Applicants the Response to Missing Parts dated July 1, 2002, including the sequence listing and sequence diskette.

3.   It is my understanding that according to our firm practice at this time, sequence listings were prepared by our paralegal department using the PatentIn software. The paralegal department would save three copies of the electronic sequence listing in ASCII format to three

Serial No. 10/010,942   ELN-002

separate diskettes: one USPTO copy, one file copy; and one client copy. The sequence diskettes were then delivered by the paralegal department to the responsible attorney.

4.   It is also my understanding that prior to mailing a response to the USPTO which included a sequence diskette, it was our firm practice to confirm the content of the diskette.

5.   I declare further that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under §1001 of Title XVIII of the United States Code, and that such willful false statements may jeopardize the validity of this Application for Patent or any patent issuing thereon.

Date: February 26, 2007   Signed: _____
                                                 Debra J. Milasincic

2

EXHIBIT 12

Office No. ELN-002

THE "RECEIVED" STAMP OF THE PATENT AND TRADEMARK OFFICE
IMPRINTED HEREON ACKNOWLEDGES THE FILING OF:

Description of Paper² and No.: Transmittal Letter (1 page, in duplicate); Response to Notice to Comply
with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence
Disclosures (2 pages); Transmittal Letter for Diskette Containing Substitute Sequence Listing (1 page); Diskette
Containing Computer Readable Form of Substitute Sequence Listing; Paper Copy of Substitute Sequence
Listing (pages 1-22); Copy of Notice to Comply with Requirements for Patent Applications Containing
Nucleotide Sequence and/or Amino Acid Sequence Disclosures (1 page); and this prepaid acknowledgment
postcard.

Title: *Humanized Antibodies That Recognize Beta Amyloid Peptide*

Name of Applicants: Guriq Basi, *et al*

Int. or Serial No.: 10/010942

Attorneys: ABM/DJM/CEH   Date: September 16, 2002

"with Certificate of First Class Mailing"

≈ 0.37 ≈

PB METER
7107161 U.S. POSTAGE

NO POSTAGE STAMP NECESSARY
POSTAGE HAS BEEN PREPAID BY

LAHIVE & COCKFIELD, LLP
28 STATE STREET
BOSTON, MA 02109

RECEIVED
LAHIVE & COCKFIELD
DOCKET DEPT.

SEP 2 6 2002

RETRIEVED:
FORWARDED

For 3½" Disk

AVERY

Disk Mailer

≪ Pull Tab to Open

LAHIVE & COCKFIELD, LLP
28 State Street
Boston, MA 02109

SEQUENCE LISTING UNDER 37 CFR 1.825
(CORRECTED SEQUENCE)

Applicants. Basi, Guriq et al.
Serial No : 10/010,942
Filed: 2001-12-06
For: HUMANIZED ANTIBODIES THAT
RECOGNIZE BETA AMYLOID PEPTIDE
Copy USPTO
Docket No ELN-002   Date. Sept 16, 2002

---

3 5" Diskette, 1 44 MB   IBM-PC, MS-Windows

DISK MAILER

Handle With Care

FIRST CLASS MAIL

SEQUENCE LISTING UNDER 37 CFR 1.825
(CORRECTED SEQUENCE)

Applicants: Basi, Guriq et al.
Serial No.: 10/010,942
Filed: 2001-12-06
For: HUMANIZED ANTIBODIES THAT
RECOGNIZE BETA AMYLOID PEPTIDE
Copy. USPTO
Docket No.: ELN-002   Date Sept. 16, 2002

---

3 5" Diskette, 1.44 MB   IBM-PC, MS-Windows

Attorney Docket No. ELN-002   1   EXHIBIT 14

SEQUENCE LISTING

<110> Basi, Guriq
      Saldanha, Jose
      Yednock, Ted

<120> HUMANIZED ANTIBODIES THAT RECOGNIZE
      BETA AMYLOID PEPTIDE

<130> ELN-002

<140> US 10/010,942
<141> 2001-12-06

<150> US 60/251,892
<151> 2000-12-06

<160> 63

<170> FastSEQ for Windows Version 4.0

<210> 1
<211> 396
<212> DNA
<213> Mus musculus

<220>
<221> CDS
<222> (1)...(396)

<221> sig_peptide
<222> (1)...(60)

<400> 1
atg atg agt cct gcc cag ttc ctg ttt ctg tta gtg ctc tgg att cgg   48
Met Met Ser Pro Ala Gln Phe Leu Phe Leu Leu Val Leu Trp Ile Arg
-20   -15   -10   -5

gaa acc aac ggt tat gtt gtg atg acc cag act cca ctc act ttg tcg   96
Glu Thr Asn Gly Tyr Val Val Met Thr Gln Thr Pro Leu Thr Leu Ser
                 1   5   10

gtt acc att gga caa cca gcc tcc atc tct tgc aag tca agt cag agc   144
Val Thr Ile Gly Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser
             15   20   25

ctc tta gat agt gat gga aag aca tat ttg aat tgg ttg tta cag agg   192
Leu Leu Asp Ser Asp Gly Lys Thr Tyr Leu Asn Trp Leu Leu Gln Arg
         30   35   40

cca ggc cag tct cca aag cgc cta atc tat ctg gtg tct aaa ctg gac   240
Pro Gly Gln Ser Pro Lys Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp
45   50   55   60

tct gga gtc cct gac agg ttc act ggc agt gga tca ggg aca gat ttt   288
Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe
             65   70   75

Attorney Docket No. ELN-007   2

```
aca ctg aaa atc agc aga ata gag gct gag gat ttg gga ctt tat tat    336
Thr Leu Lys Ile Ser Arg Ile Glu Ala Glu Asp Leu Gly Leu Tyr Tyr
            80              85              90

tgc tgg caa ggt aca cat ttt cct cgg acg ttc ggt gga ggc acc aag    384
Cys Trp Gln Gly Thr His Phe Pro Arg Thr Phe Gly Gly Gly Thr Lys
        95              100             105

ctg gaa atc aaa                                                    396
Leu Glu Ile Lys
    110
```

<210> 2
<211> 132
<212> PRT
<213> Mus musculus

<220>
<221> SIGNAL
<222> (1)...(20)

<400> 2
```
Met Met Ser Pro Ala Gln Phe Leu Phe Leu Leu Val Leu Trp Ile Arg
-20              -15             -10                 -5
Glu Thr Asn Gly Tyr Val Val Met Thr Gln Thr Pro Leu Thr Leu Ser
            1               5               10
Val Thr Ile Gly Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser
            15              20              25
Leu Leu Asp Ser Asp Gly Lys Thr Tyr Leu Asn Trp Leu Leu Gln Arg
            30              35              40
Pro Gly Gln Ser Pro Lys Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp
45              50              55              60
Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe
                65              70              75
Thr Leu Lys Ile Ser Arg Ile Glu Ala Glu Asp Leu Gly Leu Tyr Tyr
            80              85              90
Cys Trp Gln Gly Thr His Phe Pro Arg Thr Phe Gly Gly Gly Thr Lys
        95              100             105
Leu Glu Ile Lys
    110
```

<210> 3
<211> 414
<212> DNA
<213> Mus musculus

<220>
<221> CDS
<222> (1)...(414)

<221> sig_peptide
<222> (1)...(57)

<400> 3

Attorney Docket No. ELN-007( )   3

```
atg aac ttc ggg ctc agc ttg att ttc ctt gtc ctt gtt tta aaa ggt    48
Met Asn Phe Gly Leu Ser Leu Ile Phe Leu Val Leu Val Leu Lys Gly
            -15                 -10                 -5

gtc cag tgt gaa gtg aag ctg gtg gag tct ggg gga ggc tta gtg aag    96
Val Gln Cys Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Lys
            1               5                   10

cct gga gcg tct ctg aaa ctc tcc tgt gca gcc tct gga ttc act ttc   144
Pro Gly Ala Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe
        15              20                  25

agt aac tat ggc atg tct tgg gtt cgc cag aat tca gac aag agg ctg   192
Ser Asn Tyr Gly Met Ser Trp Val Arg Gln Asn Ser Asp Lys Arg Leu
30              35                  40                  45

gag tgg gtt gca tcc att agg agt ggt ggt ggt aga acc tac tat tca   240
Glu Trp Val Ala Ser Ile Arg Ser Gly Gly Gly Arg Thr Tyr Tyr Ser
                50                  55                  60

gac aat gta aag ggc cga ttc acc atc tcc aga gag aat gcc aag aac   288
Asp Asn Val Lys Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn
                65                  70                  75

acc ctg tac ctg caa atg agt agt ctg aag tct gag gac acg gcc ttg   336
Thr Leu Tyr Leu Gln Met Ser Ser Leu Lys Ser Glu Asp Thr Ala Leu
            80                  85                  90

tat tat tgt gtc aga tat gat cac tat agt ggt agc tcc gac tac tgg   384
Tyr Tyr Cys Val Arg Tyr Asp His Tyr Ser Gly Ser Ser Asp Tyr Trp
        95                  100                 105

ggc cag ggc acc act gtc aca gtc tcc tca                           414
Gly Gln Gly Thr Thr Val Thr Val Ser Ser
110                 115
```

```
<210> 4
<211> 138
<212> PRT
<213> Mus musculus

<220>
<221> SIGNAL
<222> (1)...(19)

<400> 4
Met Asn Phe Gly Leu Ser Leu Ile Phe Leu Val Leu Val Leu Lys Gly
            -15                 -10                 -5
Val Gln Cys Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Lys
            1               5                   10
Pro Gly Ala Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe
        15              20                  25
Ser Asn Tyr Gly Met Ser Trp Val Arg Gln Asn Ser Asp Lys Arg Leu
30              35                  40                  45
Glu Trp Val Ala Ser Ile Arg Ser Gly Gly Gly Arg Thr Tyr Tyr Ser
                50                  55                  60
```

Attorney Docket No. ELN-002   4

```
Asp Asn Val Lys Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn
            65                  70                  75
Thr Leu Tyr Leu Gln Met Ser Ser Leu Lys Ser Glu Asp Thr Ala Leu
        80                  85                  90
Tyr Tyr Cys Val Arg Tyr Asp His Tyr Ser Gly Ser Ser Asp Tyr Trp
    95                  100                 105
Gly Gln Gly Thr Thr Val Thr Val Ser Ser
110                 115
```

```
<210> 5
<211> 132
<212> PRT
<213> Artificial Sequence

<220>
<221> SIGNAL
<222> (1)...(20)

<223> humanized 3D6 light chain variable region

<400> 5
Met Met Ser Pro Ala Gln Phe Leu Phe Leu Leu Val Leu Trp Ile Arg
-20                 -15                 -10                 -5
Glu Thr Asn Gly Tyr Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro
            1                   5                   10
Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser
        15                  20                  25
Leu Leu Asp Ser Asp Gly Lys Thr Tyr Leu Asn Trp Leu Leu Gln Lys
        30                  35                  40
Pro Gly Gln Ser Pro Gln Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp
45                  50                  55                  60
Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe
                65                  70                  75
Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr
            80                  85                  90
Cys Trp Gln Gly Thr His Phe Pro Arg Thr Phe Gly Gln Gly Thr Lys
        95                  100                 105
Val Glu Ile Lys
    110
```

```
<210> 6
<211> 125
<212> PRT
<213> Homo sapiens

<220>
<221> SIGNAL
<222> (1)...(13)

<400> 6
Met Gly Leu Leu Met Leu Trp Val Ser Gly Ser Ser Gly Asp Ile Val
            -10                 -5                  1
Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala
    5                   10                  15
Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser Asn Gly Tyr
```

Attorney Docket No. BLN-00?⁓   5   ⁓

```
20                      25                      30              .       35
Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu
            40                      45                      50
Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro Asp Arg Phe
            55                      60                      65
Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val
            70                      75                      80
Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala Leu Gln Thr
        85                      90                      95
Pro Arg Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100                     105                     110
```

<210> 7
<211> 100
<212> PRT
<213> Homo sapiens

<400> 7
```
Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
  1               5                   10              .       15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser
            20                      25                      30  .
Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser
        35                      40                      45
Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro
    50                      55                      60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65                      70                      75                  80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala
                85                      90                      95
Leu Gln Thr Pro
            100
```

<210> 8
<211> 138
<212> PRT
<213> Artificial Sequence

<220>
<223> Humanized 3D6 heavy chain variable region

<221> SIGNAL
<222> (1)...(19)

<400> 8
```
Met Asn Phe Gly Leu Ser Leu Ile Phe Leu Val Leu Val Leu Lys Gly
                -15                 -10                     -5
Val Gln Cys Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln
            1                   5                   10
Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe
    15                      20                      25
Ser Asn Tyr Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu
30                      35                      40                  45
Glu Trp Val Ala Ser Ile Arg Ser Gly Gly Gly Arg Thr Tyr Tyr Ser
                50                      55                      60
Asp Asn Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn
```

Attorney Docket No. ELN-00？（ ）   6   （ ）

```
                 65                    70                    75
Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu
        80                    85                    90
Tyr Tyr Cys Val Arg Tyr Asp His Tyr Ser Gly Ser Ser Asp Tyr Trp
    95                    100                   105
Gly Gln Gly Thr Leu Val Thr Val Ser Ser
110                   115
```

```
<210> 9
<211> 121
<212> PRT
<213> Homo sapiens

<400> 9
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
    1               5                   10                  15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
        20                    25                    30
Ala Val Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
        35                    40                    45
Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
        50                    55                    60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
65                    70                    75                    80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys
                85                    90                    95
Ala Lys Asp Asn Tyr Asp Phe Trp Ser Gly Thr Phe Asp Tyr Trp Gly
                100                   105                   110
Gln Gly Thr Leu Val Thr Val Ser Ser
            115                   120
```

```
<210> 10
<211> 98
<212> PRT
<213> Homo sapiens

<400> 10
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
    1               5                   10                  15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
        20                    25                    30
Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
        35                    40                    45
Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
        50                    55                    60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                    70                    75                    80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                    90                    95
Ala Lys
```

```
<210> 11
<211> 132
```

```
<212> PRT
<213> Artificial Sequence

<220>
<221> SIGNAL
<222> (1)...(20)

<223> humanized 3D6 light chain variable region

<400> 11
Met Met Ser Pro Ala Gln Phe Leu Phe Leu Leu Val Leu Trp Ile Arg
-20              -15                  -10                  -5
Glu Thr Asn Gly Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro
                1                5                  10
Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser
        15              20                  25
Leu Leu Asp Ser Asp Gly Lys Thr Tyr Leu Asn Trp Leu Leu Gln Lys
    30                  35                  40
Pro Gly Gln Ser Pro Gln Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp
45                  50                  55                  60
Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe
                65                  70                  75
Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr
            80                  85                  90
Cys Trp Gln Gly Thr His Phe Pro Arg Thr Phe Gly Gln Gly Thr Lys
        95                  100                 105
Val Glu Ile Lys
    110


<210> 12
<211> 138
<212> PRT
<213> Artificial Sequence

<220>
<223> Humanized 3D6 light chain variable region

<221> SIGNAL
<222> (1)...(19)

<400> 12
Met Asn Phe Gly Leu Ser Leu Ile Phe Leu Val Leu Val Leu Lys Gly
                -15                  -10                  -5
Val Gln Cys Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln
                1                5                  10
Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe
        15              20                  25
Ser Asn Tyr Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu
30                  35                  40                  45
Glu Trp Val Ala Ser Ile Arg Ser Gly Gly Gly Arg Thr Tyr Tyr Ser
                50                  55                  60
Asp Asn Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn
            65                  70                  75
Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val
        80                  85                  90
Tyr Tyr Cys Val Arg Tyr Asp His Tyr Ser Gly Ser Ser Asp Tyr Trp
```

```
       95                    100                    105
Gly Gln Gly Thr Leu Val Thr Val Ser Ser
110                    115
```

<210> 13
<211> 393
<212> DNA
<213> Mus musculus

<220>
<221> CDS
<222> (1)...(393)

<221> sig_peptide
<222> (1)...(57)

<400> 13
```
atg aag ttg cct gtt agg ctg ttg gta ctg atg ttc tgg att cct gct    48
Met Lys Leu Pro Val Arg Leu Leu Val Leu Met Phe Trp Ile Pro Ala
                -15                    -10                    -5

tcc agc agt gat gtt ttg atg acc caa act cca ctc tcc ctg cct gtc    96
Ser Ser Ser Asp Val Leu Met Thr Gln Thr Pro Leu Ser Leu Pro Val
                 1                    5                    10

agt ctt gga gat caa gcc tcc atc tct tgc aga tct agt cag aac att   144
Ser Leu Gly Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Asn Ile
        15                    20                    25

ata cat agt aat gga aac acc tat tta gaa tgg tac ctg cag aaa cca   192
Ile His Ser Asn Gly Asn Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro
30                    35                    40                    45

ggc cag tct cca aag ctc ctg atc tac aaa gtt tcc aac cga ttt tct   240
Gly Gln Ser Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser
                50                    55                    60

ggg gtc cca gac agg ttc agt ggc agt gga tca ggg aca gat ttc aca   288
Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr
                65                    70                    75

ctc aag atc aag aaa gtg gag gct gag gat ctg gga att tat tac tgc   336
Leu Lys Ile Lys Lys Val Glu Ala Glu Asp Leu Gly Ile Tyr Tyr Cys
                80                    85                    90

ttt caa ggt tca cat gtt ccg ctc acg ttc ggt gct ggg acc aag ctg   384
Phe Gln Gly Ser His Val Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu
        95                    100                    105

gag ctg gaa                                                        393
Glu Leu Glu
110
```

<210> 14
<211> 131

```
<212> PRT
<213> Mus musculus

<220>
<221> SIGNAL
<222> (1)...(19)

<400> 14
Met Lys Leu Pro Val Arg Leu Leu Val Leu Met Phe Trp Ile Pro Ala
            -15              -10                  -5
Ser Ser Ser Asp Val Leu Met Thr Gln Thr Pro Leu Ser Leu Pro Val
             1               5                   10
Ser Leu Gly Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Asn Ile
        15              20              25
Ile His Ser Asn Gly Asn Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro
30              35              40                      45
Gly Gln Ser Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser
            50                  55                  60
Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr
            65                  70                  75
Leu Lys Ile Lys Lys Val Glu Ala Glu Asp Leu Gly Ile Tyr Tyr Cys
        80                  85                  90
Phe Gln Gly Ser His Val Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu
        95              100                 105
Glu Leu Glu
110


<210> 15
<211> 426
<212> DNA
<213> Mus musculus

<220>
<221> CDS
<222> (1)...(426)

<221> sig_peptide
<222> (1)...(57)

<400> 15
atg gac agg ctt act tcc tca ttc ctg ctg ctg att gtc cct gca tat    48
Met Asp Arg Leu Thr Ser Ser Phe Leu Leu Leu Ile Val Pro Ala Tyr
             -15              -10                 -5

gtc ctg tcc cag gct act ctg aaa gag tct ggc cct gga ata ttg cag    96
Val Leu Ser Gln Ala Thr Leu Lys Glu Ser Gly Pro Gly Ile Leu Gln
             1               5                   10

tcc tcc cag acc ctc agt ctg act tgt tct ttc tct ggg ttt tca ctg   144
Ser Ser Gln Thr Leu Ser Leu Thr Cys Ser Phe Ser Gly Phe Ser Leu
        15              20              25

agc act tct ggt atg gga gtg agc tgg att cgt cag cct tca gga aag   192
Ser Thr Ser Gly Met Gly Val Ser Trp Ile Arg Gln Pro Ser Gly Lys
        30              35              40                      45
```

Attorney Docket No. ELN-002;   10

```
ggt ctg gag tgg ctg gca cac att tac tgg gat gat gac aag cgc tat    240
Gly Leu Glu Trp Leu Ala His Ile Tyr Trp Asp Asp Asp Lys Arg Tyr
            50                  55                  60

aac cca tcc ctg aag agc cgg ctc aca atc tcc aag gat acc tcc aga    288
Asn Pro Ser Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Arg
            65                  70                  75

aag cag gta ttc ctc aag atc acc agt gtg gac cct gca gat act gcc    336
Lys Gln Val Phe Leu Lys Ile Thr Ser Val Asp Pro Ala Asp Thr Ala
            80                  85                  90

aca tac tac tgt gtt cga agg ccc att act ccg gta cta gtc gat gct    384
Thr Tyr Tyr Cys Val Arg Arg Pro Ile Thr Pro Val Leu Val Asp Ala
            95                  100                 105

atg gac tac tgg ggt caa gga acc tca gtc acc gtc tcc tca            426
Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser
110                 115                 120
```

```
<210> 16
<211> 142
<212> PRT
<213> Mus musculus

<220>
<221> SIGNAL
<222> (1)...(19)

<400> 16
Met Asp Arg Leu Thr Ser Ser Phe Leu Leu Leu Ile Val Pro Ala Tyr
            -15                 -10                 -5
Val Leu Ser Gln Ala Thr Leu Lys Glu Ser Gly Pro Gly Ile Leu Gln
            1                   5                   10
Ser Ser Gln Thr Leu Ser Leu Thr Cys Ser Phe Ser Gly Phe Ser Leu
            15                  20                  25
Ser Thr Ser Gly Met Gly Val Ser Trp Ile Arg Gln Pro Ser Gly Lys
30                  35                  40                  45
Gly Leu Glu Trp Leu Ala His Ile Tyr Trp Asp Asp Asp Lys Arg Tyr
            50                  55                  60
Asn Pro Ser Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Arg
            65                  70                  75
Lys Gln Val Phe Leu Lys Ile Thr Ser Val Asp Pro Ala Asp Thr Ala
            80                  85                  90
Thr Tyr Tyr Cys Val Arg Arg Pro Ile Thr Pro Val Leu Val Asp Ala
            95                  100                 105
Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser
110                 115                 120
```

```
<210> 17
<211> 136
<212> DNA
<213> Artificial Sequence

<220>
```

Attorney Docket No. ELN-002   11   ( )

```
<223> primer

<400> 17
tccgcaagct tgccgccacc atggacatgc gcgtgcccgc ccagctgctg ggcctgctga 60
tgctgtgggt gtccggctcc tccggctacg tggtgatgac ccagtccccc ctgtccctgc 120
ccgtgacccc cggcga                                                  136

<210> 18
<211> 131
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 18
ctggggggac tggccgggct tctgcagcag ccagttcagg taggtcttgc cgtcggagtc 60
cagcagggac tggaggact tgcaggagat ggaggcgggc tcgccggggg tcacgggcag 120
ggacaggggg g                                                      131

<210> 19
<211> 146
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 19
acctgaactg gctgctgcag aagcccggcc agtccccca gcgcctgatc tacctggtgt 60
ccaagctgga ctccggcgtg cccgaccgct tctccggctc cggctccggc accgacttca 120
ccctgaagat ctcccgcgtg gaggcc                                      146

<210> 20
<211> 142
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 20
aattctagga tccactcacg cttgatctcc accttggtgc cctggccgaa ggtgcggggg 60
aagtgggtgc cctgccagca gtagtacacg cccacgtcct cggcctccac gcgggagatc 120
ttcagggtga agtcggtgcc gg                                          142

<210> 21
<211> 16
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 21
ctggggggac tggccg                                                 16
```

Attorney Docket No. ELN-00?   12

```
<210> 22
<211> 22
<212> DNA
<<213> Artificial Sequence

<220>
<223> primer

<400> 22
acctgaactg gctgctgcag aa                                                22

<210> 23
<211> 138
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 23
acagaaagct tgccgccacc atggagtttg ggctgagctg gctttttctt gtggctattt  60
taaaaggtgt ccagtgtgag gtgcagctgc tggagtccgg cggcggcctg gtgcagcccg  120
gcggctccct gcgcctgt                                                 138

<210> 24
<211> 135
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 24
gccgccggag cggatggagg ccacccactc caggcccttg ccggggggcct ggcgcaccca  60
ggacatgccg tagttggaga aggtgaagcc ggaggcggcg caggacaggc gcagggagcc  120
gccgggctgc accag                                                    135

<210> 25
<211> 142
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 25
ctggagtggg tggcctccat ccgctccggc ggcggccgca cctactactc cgacaacgtg  60
aagggccgct tcaccatctc ccgcgacaac gccaagaact ccctgtacct gcagatgaac  120
tccctgcgcg ccgaggacac cg                                            142

<210> 26
<211> 144
<212> DNA
<213> Artificial Sequence

<220>
<223> primer
```

```
<400> 26
ctgcaaggat ccactcaccg gaggacacgg tcaccagggt gccctggccc cagtagtcgg 60
aggagccgga gtagtggtcg tagcgcacgc agtagtacag ggcggtgtcc tcggcgcgca 120
gggagttcat ctgcaggtac aggg 144

<210> 27
<211> 16
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 27
gccgccggag cggatg 16

<210> 28
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 28
ctggagtggg tggcctccat 20

<210> 29
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 29
tccgcaagct tgccgccac 19

<210> 30
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 30
aattctagga tccactcacg cttgatctc 29

<210> 31
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> primer
```

Attorney Docket No. ELN-002   14

<400> 31
acagaaagct tgccgccacc atg   23

<210> 32
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 32
ctgcaaggat ccactcaccg ga   22

<210> 33
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> native ABeta peptide

<400> 33
Asp Ala Glu Phe Arg His Asp Ser Gly Tyr
1   5   10

<210> 34
<211> 402
<212> DNA
<213> Artificial Sequence

<220>
<223> h3D6 version 1 VL

<400> 34
atggacatgc gcgtgcccgc ccagctgctg ggcctgctga tgctgtgggt gtccggctcc 60
tccggctacg tggtgatgac ccagtccccc ctgtccctgc ccgtgacccc cggcgagccc 120
gcctccatct cctgcaagtc ctcccagtcc ctgctggact ccgacggcaa gacctacctg 180
aactggctgc tgcagaagcc cggccagtcc ccccagcgcc tgatctacct ggtgtccaag 240
ctggactccg gcgtgcccga ccgcttctcc ggctccggct ccggcaccga cttcaccctg 300
aagatctccc gcgtggaggc cgaggacgtg ggcgtgtact actgctggca gggcacccac 360
ttccccccgca ccttcggcca gggcaccaag gtggagatca ag   402

<210> 35
<211> 402
<212> DNA
<213> Artificial Sequence

<220>
<223> h3D6 version 2 VL

<400> 35
atggacatgc gcgtgcccgc ccagctgctg ggcctgctga tgctgtgggt gtccggctcc 60
tccggcgacg tggtgatgac ccagtccccc ctgtccctgc ccgtgacccc cggcgagccc 120
gcctccatct cctgcaagtc ctcccagtcc ctgctggact ccgacggcaa gacctacctg 180

Attorney Docket No. ELN-00? 15

```
aactggctgc tgcagaagcc cggccagtcc ccccagcgcc tgatctacct ggtgtccaag 240
ctggactccg gcgtgcccga ccgcttctcc ggctccggct ccggcaccga cttcaccctg 300
aagatctccc gcgtggaggc cgaggacgtg ggcgtgtact actgctggca gggcacccac 360
ttcccccgca ccttcggcca gggcaccaag gtggagatca ag                    402
```

<210> 36
<211> 414
<212> DNA
<213> Artificial Sequence

<220>
<223> h3D6 version 1 VH

<400> 36
```
atggagtttg ggctgagctg gctttttctt gtggctattt taaaaggtgt ccagtgtgag 60
gtgcagctgc tggagtccgg cggcggcctg gtgcagcccg cggctccct cgcctgtcc 120
tgcgccgcct ccggcttcac cttctccaac tacggcatgt cctgggtgcg ccaggccccc 180
ggcaagggcc tggagtgggt ggcctccatc cgctccggcg cggccgcac ctactactcc 240
gacaacgtga agggccgctt caccatctcc cgcgacaacg ccaagaactc cctgtacctg 300
cagatgaact ccctgcgcgc cgaggacacc gccctgtact actgcgtgcg ctacgaccac 360
tactccggct cctccgacta ctggggccag ggcaccctgg tgaccgtgtc ctcc        414
```

<210> 37
<211> 414
<212> DNA
<213> Artificial Sequence

<220>
<223> h3D6 version 2 VH

<400> 37
```
atggagtttg ggctgagctg gctttttctt gtggctattt taaaaggtgt ccagtgtgag 60
gtgcagctgc tggagtccgg cggcggcctg gtgcagcccg cggctccct cgcctgtcc 120
tgcgccgcct ccggcttcac cttctccaac tacggcatgt cctgggtgcg ccaggccccc 180
ggcaagggcc tggagtgggt ggcctccatc cgctccggcg cggccgcac ctactactcc 240
gacaacgtga agggccgctt caccatctcc cgcgacaact ccaagaacac cctgtacctg 300
cagatgaact ccctgcgcgc cgaggacacc gccgtgtact actgcgtgcg ctacgaccac 360
tactccggct cctccgacta ctggggccag ggcaccctgg tgaccgtgtc ctcc        414
```

<210> 38
<211> 770
<212> PRT
<213> Homo sapiens

<400> 38
```
Met Leu Pro Gly Leu Ala Leu Leu Leu Ala Ala Trp Thr Ala Arg
1               5                   10                  15
Ala Leu Glu Val Pro Thr Asp Gly Asn Ala Gly Leu Leu Ala Glu Pro
            20                  25                  30
Gln Ile Ala Met Phe Cys Gly Arg Leu Asn Met His Met Asn Val Gln
        35                  40                  45
Asn Gly Lys Trp Asp Ser Asp Pro Ser Gly Thr Lys Thr Cys Ile Asp
    50                  55                  60
Thr Lys Glu Gly Ile Leu Gln Tyr Cys Gln Glu Val Tyr Pro Glu Leu
65                  70                  75                  80
Gln Ile Thr Asn Val Val Glu Ala Asn Gln Pro Val Thr Ile Gln Asn
                85                  90                  95
```

```
Trp Cys Lys Arg Gly Arg Lys Gln Cys Lys Thr His Pro His Phe Val
        100                 105                 110
Ile Pro Tyr Arg Cys Leu Val Gly Glu Phe Val Ser Asp Ala Leu Leu
        115                 120                 125
Val Pro Asp Lys Cys Lys Phe Leu His Gln Glu Arg Met Asp Val Cys
    130                 135                 140
Glu Thr His Leu His Trp His Thr Val Ala Lys Glu Thr Cys Ser Glu
145                 150                 155                 160
Lys Ser Thr Asn Leu His Asp Tyr Gly Met Leu Leu Pro Cys Gly Ile
                165                 170                 175
Asp Lys Phe Arg Gly Val Glu Phe Val Cys Cys Pro Leu Ala Glu Glu
            180                 185                 190
Ser Asp Asn Val Asp Ser Ala Asp Ala Glu Glu Asp Asp Ser Asp Val
        195                 200                 205
Trp Trp Gly Gly Ala Asp Thr Asp Tyr Ala Asp Gly Ser Glu Asp Lys
    210                 215                 220
Val Val Glu Val Ala Glu Glu Glu Glu Val Ala Glu Val Glu Glu Glu
225                 230                 235                 240
Glu Ala Asp Asp Asp Glu Asp Asp Glu Asp Gly Asp Glu Val Glu Glu
            245                 250                 255
Glu Ala Glu Glu Pro Tyr Glu Glu Ala Thr Glu Arg Thr Thr Ser Ile
            260                 265                 270
Ala Thr Thr Thr Thr Thr Thr Thr Glu Ser Val Glu Glu Val Val Arg
        275                 280                 285
Glu Val Cys Ser Glu Gln Ala Glu Thr Gly Pro Cys Arg Ala Met Ile
    290                 295                 300
Ser Arg Trp Tyr Phe Asp Val Thr Glu Gly Lys Cys Ala Pro Phe Phe
305                 310                 315                 320
Tyr Gly Gly Cys Gly Gly Asn Arg Asn Asn Phe Asp Thr Glu Glu Tyr
                325                 330                 335
Cys Met Ala Val Cys Gly Ser Ala Met Ser Gln Ser Leu Leu Lys Thr
            340                 345                 350
Thr Gln Glu Pro Leu Ala Arg Asp Pro Val Lys Leu Pro Thr Thr Ala
        355                 360                 365
Ala Ser Thr Pro Asp Ala Val Asp Lys Tyr Leu Glu Thr Pro Gly Asp
    370                 375                 380
Glu Asn Glu His Ala His Phe Gln Lys Ala Lys Glu Arg Leu Glu Ala
385                 390                 395                 400
Lys His Arg Glu Arg Met Ser Gln Val Met Arg Glu Trp Glu Glu Ala
            405                 410                 415
Glu Arg Gln Ala Lys Asn Leu Pro Lys Ala Asp Lys Lys Ala Val Ile
        420                 425                 430
Gln His Phe Gln Glu Lys Val Glu Ser Leu Glu Gln Glu Ala Ala Asn
        435                 440                 445
Glu Arg Gln Gln Leu Val Glu Thr His Met Ala Arg Val Glu Ala Met
    450                 455                 460
Leu Asn Asp Arg Arg Arg Leu Ala Leu Glu Asn Tyr Ile Thr Ala Leu
465                 470                 475                 480
Gln Ala Val Pro Pro Arg Pro Arg His Val Phe Asn Met Leu Lys Lys
                485                 490                 495
Tyr Val Arg Ala Glu Gln Lys Asp Arg Gln His Thr Leu Lys His Phe
            500                 505                 510
Glu His Val Arg Met Val Asp Pro Lys Lys Ala Ala Gln Ile Arg Ser
        515                 520                 525
Gln Val Met Thr His Leu Arg Val Ile Tyr Glu Arg Met Asn Gln Ser
    530                 535                 540
Leu Ser Leu Leu Tyr Asn Val Pro Ala Val Ala Glu Glu Ile Gln Asp
```

Attorney Docket No. ELN-002   17

```
         545                     550                     555                     560
         Glu Val Asp Glu Leu Leu Gln Lys Glu Gln Asn Tyr Ser Asp Asp Val
                         565                     570                     575
         Leu Ala Asn Met Ile Ser Glu Pro Arg Ile Ser Tyr Gly Asn Asp Ala
                     580                     585                     590
         Leu Met Pro Ser Leu Thr Glu Thr Lys Thr Thr Val Glu Leu Leu Pro
                 595                     600                     605
         Val Asn Gly Glu Phe Ser Leu Asp Asp Leu Gln Pro Trp His Ser Phe
             610                     615                     620
         Gly Ala Asp Ser Val Pro Ala Asn Thr Glu Asn Glu Val Glu Pro Val
         625                 630                     635                     640
         Asp Ala Arg Pro Ala Ala Asp Arg Gly Leu Thr Thr Arg Pro Gly Ser
                         645                     650                     655
         Gly Leu Thr Asn Ile Lys Thr Glu Glu Ile Ser Glu Val Lys Met Asp
                     660                     665                     670
         Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys Leu
                 675                     680                     685
         Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile Gly
             690                     695                     700
         Leu Met Val Gly Gly Val Val Ile Ala Thr Val Ile Val Ile Thr Leu
         705                     710                     715                     720
         Val Met Leu Lys Lys Lys Gln Tyr Thr Ser Ile His His Gly Val Val
                         725                     730                     735
         Glu Val Asp Ala Ala Val Thr Pro Glu Glu Arg His Leu Ser Lys Met
                     740                     745                     750
         Gln Gln Asn Gly Tyr Glu Asn Pro Thr Tyr Lys Phe Phe Glu Gln Met
                 755                     760                     765
         Gln Asn
         770
```

```
<210> 39
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 39
actagtcgac atgaagttgc ctgttaggct gttggtgctg                          40


<210> 40
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 40
actagtcgac atggagwcag acacactcct gytatgggt                           39


<210> 41
<211> 40
<212> DNA
<213> Artificial Sequence
```

```
<220>
<223> primer

<400> 41
actagtcgac atgagtgtgc tcattcaggt cctggsgttg                    40

<210> 42
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 42
actagtcgac atgaggrccc ctgctcagwt tyttggmwtc ttg               43

<210> 43
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 43
actagtcgac atggatttwc aggtgcagat twtcagcttc                    40

<210> 44
<211> 37
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 44
actagtcgac atgaggtkcy ytgytsagyt yctgrgg                       37

<210> 45
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 45
actagtcgac atgggcwtca agatggagtc acakwyycwg g                  41

<210> 46
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
```

Attorney Docket No. ELN-007   19

<223> primer

<400> 46
actagtcgac atgtggggay ctktttycmm tttttcaatt g   41

<210> 47
<211> 35
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 47
actagtcgac atggtrtccw casctcagtt ccttg   35

<210> 48
<211> 37
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 48
actagtcgac atgtatatat gtttgttgtc tatttct   37

<210> 49
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 49
actagtcgac atggaagccc cagctcagct tctcttcc   38

<210> 50
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 50
ggatcccggg tggatggtgg gaagatg   27

<210> 51
<211> 37
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

Attorney Docket No. ELN-002

20

```
<400> 51
actagtcgac atgaaatgca gctgggtcat sttcttc                              37

<210> 52
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 52
actagtcgac atgggatgga gctrtatcat sytctt                               36

<210> 53
<211> 37
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 53
actagtcgac atgaagwtgt ggttaaactg ggttttt                              37

<210> 54
<211> 35
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 54
actagtcgac atgractttg ggytcagctt grttt                                35

<210> 55
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 55
actagtcgac atggactcca ggctcaattt agttttcctt                           40

<210> 56
<211> 37
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 56
actagtcgac atggctgtcy trgsgctrct cttctgc                              37
```

```
<210> 57
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 57
actagtcgac atggratgga gckggrtctt tmtctt                           36

<210> 58
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 58
actagtcgac atgagagtgc tgattctttt gtg                             33

<210> 59
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 59
actagtcgac atggmttggg tgtggamctt gctattcctg                      40

<210> 60
<211> 37
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 60
actagtcgac atgggcagac ttacattctc attcctg                         37

<210> 61
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 61
actagtcgac atggattttg ggctgatttt ttttattg                        38

<210> 62
```

Attorney Docket No. ELN-00₂‾⁻₍   22

```
<211> 37
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 62
actagtcgac atgatggtgt taagtcttct gtacctg                                    37

<210> 63
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 63
ggatcccggg agtggataga ctgatgg                                               27
```

EXHIBIT 15

Docket No.: ELN-002
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Guriq Basi *et al.*

Application No.: 10/010942

Filed: December 6, 2001

For: HUMANIZED ANTIBODIES THAT
RECOGNIZE BETA AMYLOID PEPTIDE

Confirmation No.: 5594

Art Unit: 1649

Examiner: Ballard, Kimberly A.

MS Petition
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

STATEMENT

Dear Sir:

I hereby state that I have reviewed the paper copy of the Sequence Listing identified as Exhibit 6, and have reviewed the paper copy of the Sequence Listing identified as Exhibit 14, and further state that the contents of these Sequence Listings are the same.

Dated: February 26, 2007

Respectfully submitted,

By _____
Amy E. Mandragouras
Registration No.: 36,207
LAHIVE & COCKFIELD, LLP
28 State Street
Boston, Massachusetts 02109
(617) 227-7400
(617) 742-4214 (Fax)
Attorney/Agent For Applicant

EXHIBIT 16

Duplicates in View of USPS Mail Delays - OG Date: 15 January 2002   Page 1 of 3

United States Patent and Trademark Office <u>OG Notices: 15 January 2002</u>

Processing of, and Requirements for, the Filing of
Duplicate Applications and Papers in
Patent Applications in view of USPS Mail Delays

Although mailed correspondence is being received by the United
States Patent and Trademark Office (USPTO or Office), many papers that
were mailed by first class mail or Express Mail through the United
States Postal Service (USPS) in October and November of 2001 have had
their delivery delayed. See Mitigation of Delays in Mail Deliveries to the
USPTO, which is posted on the USPTO Internet Web site at:
http://www.uspto.gov/september11/mitigationofmaildelays.htm.
Some of those papers still have not been received by the USPTO. Although
the USPS reports (http://www.usps.com/news/2001/press/pr01_1023fact.htm)
that "98% of mail at the Brentwood facility has been sanitized and
delivered," the USPS has also informed the USPTO that some of the
mail that was in the Brentwood Mail facility on October 21 or 22, 2001
may never be received by the USPTO because of anthrax-related
decontamination activities. Some applicants, concerned about papers
mailed during this time period that have not been received by the
USPTO, have filed duplicate copies of the original correspondence along
with a statement that meets the requirement in 37 CFR 1.8(b)(3) prior
to any holding of abandonment to permit the Office to more timely act
on the correspondence. While Office processing of such duplicates will
enable the examination process to move forward, applicants should be
aware that the submission of duplicate copies may be unnecessary (and
could slow down the processing of the application) and that double
charging (collection) of the fees may result from subsequent processing
by the Office of the delayed original, which may lead to the submission
for, and the processing of, refund requests. The Office will try,
however, to avoid double charging (collection) of fees as much as is
possible.

I. Timeliness of Replies Whose Delivery to the Office has been Delayed:

In accordance with the Office's usual practice, if a paper was
mailed with a certificate of mailing, the Office will determine the
timeliness (e.g., 35 U.S.C. 133) of the paper based on the
certificate of mailing date as set forth in 37 CFR 1.8(a). See
Manual of Patent Examining Procedure (MPEP), Eighth Edition, 512,
(August 2001). If a paper was sent by Express Mail, the Office will
determine the timeliness and filing date of the paper based on the date of
deposit with the USPS, which is the "date-in" on the Express Mail mailing
label as set forth in 37 CFR 1.10(a). See MPEP   513. Therefore, if the
procedures under 37 CFR 1.8 or 1.10 have been followed, any delays in
delivery of the paper to the Office will not impact the timeliness of the
paper. The Office will process a reply (whose delivery to the Office has
been delayed) as timely if the date on the certificate of mailing, or the
"date-in" on the Express Mail mailing label, is within the period for reply
set forth in the prior Office action or notice.

http://www.uspto.gov/web/offices/com/sol/og/2002/week03/patdups.htm   2/7/2002

II. Timeliness of Duplicate Replies Filed when the Original has not been Received by the Office:

A. If the duplicate is, itself, timely filed: If applicant submits a duplicate copy of a paper that has not been received in the Office, the duplicate paper will be processed by the Office as timely if the duplicate is filed within the period for reply to the prior Office action or notice (not considering any extensions of time that may have been available).

B. If a duplicate is filed after the expiration of reply period but with acceptable proof of prior timely filing: If the original reply was timely mailed within the period from October 13, 2001 to December 1, 2001 using the certificate of mailing procedure under 37 CFR 1.8, and a duplicate copy is received in the Office after the period for reply has expired, then the Office shall accept the duplicate as the reply, and to have been timely filed, if applicant submits:

(1) a copy of the previously mailed reply and certificate of mailing of the previously mailed reply (the certificate of mailing must be signed and the certificate of mailing must itself indicate the date of mailing); and

(2) a statement that the reply was previously mailed to the USPTO on the date indicated on the certificate of mailing.

It is not sufficient to stamp the reply "Duplicate" or "Copy" and to fax the document to the USPTO, a statement is always required. The statement can be part of the fax transmittal cover sheet or the cover letter so long as the fax transmittal sheet is signed as specified below. The statement must be signed by: the person who personally mailed the original reply, a registered patent attorney or agent, the assignee of the entire interest, or the applicant (all of the inventors or the party qualified under 37 CFR 1.42, 1.43 or 1.47). For example, the statement may be: "This is a copy of correspondence that was mailed to the USPTO on _____ date" or "This is a copy of an amendment that was mailed to the USPTO on the date of the certificate of mailing."

If a certificate of mailing as set forth in 37 CFR 1.8 was not used (or if the certificate of mailing was not signed, or if the certificate of mailing did not include a date), and applicant does not have a post card receipt for the correspondence, the Office cannot accord the duplicate correspondence any date other than the date that the duplicate was actually received in the Office. If the duplicate copy was not itself timely filed, applicant should consider filing a petition to revive under 37 CFR 1.137(a) or (b).

To the extent that this treatment of showings as set forth 37 CFR 1.8(b) (3) is less stringent than the requirements set forth in 37 CFR 1.8(b)(3), the provisions of 37 CFR 1.8(b)(3) are hereby sua sponte waived for replies mailed on or after October 13, 2001 and no later than December 1, 2001.

III. Establishing that a Paper other than a Reply was Mailed to the USPTO

A paper that is not a reply to an Office action or is not a
correspondence that is required to be filed in the USPTO within a set
period of time is NOT entitled to the benefit of a certificate of
mailing under 37 CFR 1.8(a). The filing date of such a paper is the
actual date of receipt in the USPTO, except as provided by 37 CFR 1.10.
For example, a preliminary amendment is not a reply to an Office action
and, therefore, would not receive the benefit of a certificate of
mailing under 37 CFR 1.8(a). On the other hand, an information
disclosure statement (IDS) will be considered to have been filed on the
"date that it was received in the Office, or an earlier date of
mailing if accompanied by a properly executed certificate of
mailing." See MPEP 609, page 600-124. An IDS is entitled
to the benefit of a certificate of mailing under 37 CFR 1.8(a) since
the IDS is a correspondence that is required to be filed in the USPTO
within a set period of time. To establish that a paper not entitled to
the benefit of a certificate of mailing under 37 CFR 1.8(a) was filed
in the USPTO, applicant must have used Express Mail and comply with the
provisions of 37 CFR 1.10, or have a post card receipt establishing
that the paper was actually received in the USPTO. Other than in these
circumstances, the rules do not provide a mechanism for establishing
that such a paper was filed in the USPTO.

IV. Office Will Try to Call Before Abandoning Applications Without a Reply:

In most circumstances, before holding an application to be
abandoned, staff from the Technology Centers and the Office of Patent
Publication will attempt to call applicants to see if a reply has been
previously filed. If a reply has been filed, applicant will be
requested to fax (or file) a duplicate copy of the prior (original)
paper along with a showing as set forth in 37 CFR 1.8(b)(3) in order to
avoid the application from being held abandoned.

If applicant files a duplicate with an acceptable showing as
set forth in 37 CFR 1.8(b)(3), it will avoid both the Office holding
the application as abandoned, and the processing delays associated with
the withdrawal of such abandonment.

J. Duplicate Fee Charges (Collections) are Possible When Duplicates are
Filed:

When the Office is processing a duplicate before processing the
original, the Office shall charge (collect) all fees that are due for
the proper processing of the paper, and will not process any papers
that are not accompanied by the appropriate fee. Accordingly,
applicants should expect that the same fees may inadvertently be
charged (collected) when the Office later processes the original paper.
The Office will try to avoid this type of double charging (collecting)
by checking to see if the fees required to process a delayed original
paper were previously charged (collected) and, if previously charged
(collected), the Office will not charge (collect) the fees a second
time. The Office, however, cannot guarantee that double charging
(collecting) will not occur. If the Office processes fees with both the

duplicate and then the original papers, applicant may request a refund
under 37 CFR 1.26. If the application has been allowed, the refund
request should be filed after the patent has been issued in order to
avoid printing delays. When the original paper corresponding to the
duplicate is received, the original paper will be attached to the
duplicate in the application file wrapper and will not be listed as a
separate contents entry for the application in the Office's records.
This procedure will be used notwithstanding the procedure set forth in
MPEP 719.01(a).

VI. How to File a Duplicate Reply during Examination or after Allowance:

    A. If the Application is in a Technology Center: If applicant desires to
file a duplicate copy of a reply to an Office action, with an appropriate
showing as set forth in 37 CFR 1.8(b)(3), the duplicate should be faxed to
the appropriate Technology Center. The reply facsimile numbers for each
Technology Center that should be used are posted on the USPTO Internet web
site at: http://www.uspto.gov/september11/faxnotice.htm.

    B. If the Application has been Allowed: If applicant desires to file a
duplicate Issue Fee transmittal (e.g., a duplicate PTOL-85B) in order to
pay the issue fee and any publication fee, along with a duplicate copy of
other post allowance correspondence that was submitted with the issue fee
transmittal, accompanied by an appropriate showing as set forth 37 CFR
1.8(b)(3), the duplicate submission(s) and the showing(s) should be faxed
to Box Issue Fee: (703) 746-4000. If an amendment under 37 CFR 1.312 was
mailed before payment of the issue fee, and the Office has not yet received
the amendment, applicant should include a copy of the amendment (and a
statement explaining when the amendment was filed) with the issue fee
payment so that the amendment under 37 CFR 1.312 is not treated as having
been filed after payment of the issue fee, and therefore not entered
(because amendments after payment of the issue fee are no longer
permitted).

VII. Filing of Duplicate New Applications and Replies to OIPE:

    The USPTO appreciates, that, where warranted, applicants should
take advantage of 37 CFR 1.8(b) and 1.10(e), which permits the filing
of duplicate copies of prior correspondence in place of lost or missing
originals. While applicants should, as a general rule, promptly file a
duplicate (of a new application filing or a reply to an OIPE notice)
when they become aware that the Office has not received, and may not
ever receive, an item of correspondence, the level of urgency usually
associated with such action should take into account the fact that the
USPTO expects to receive all, or substantially all, of the delayed
correspondence. In addition, correspondence will be treated as filed
(37 CFR 1.10) or timely (37 CFR 1.8), if applicant originally filed
under those provisions regardless of the length of time that the
correspondence took to reach the Office. In the event the Office has
not received the original by March 1, 2002 applicant then should file a
duplicate. The Office will mail a return post card receipt and/or
filing receipt or notice, as it usually does, when correspondence is
received by the Office so applicant will be informed when delayed

correspondence has been received.

When the USPTO receives a duplicate submission, it shall consider a showing that a reply was timely mailed as set forth 37 CFR 1.8(b), or a petition for a filing date under 37 CFR 1.10(e), to have been timely filed so long as the showing or petition is filed by May of 2002. To the extent that this standard for timeliness is less stringent than the requirements set forth in 37 CFR 1.8(b)(1), 1.10(e)(1) and 1.181(f), the provisions of 37 CFR 1.8(b)(1), 1.10(e)(1) and 1.181(f) are hereby sua sponte waived for applications and papers mailed on or after October 13, 2001 and no later than December 1, 2001. Where there is a special need, however, applicants should take advantage of the rules and file duplicates without delay. Special needs could include the following: applications and correspondence mailed on or after October 17, and before October 23, 2001 that have not yet been received by the Office, Patent Cooperation Treaty application filings where priority has been claimed, design applications, replies to a Notice of Incomplete Application (filing date not granted) which was mailed under 37 CFR 1.8, and where certified copies of an application will be needed for priority purposes. In all other situations, before filing a duplicate of a prior mailed correspondence pursuant to 37 CFR 1.8(b) and 1.10(e), applicants might want to wait to see if the original is later received.

If correspondence sent via Express Mail was returned to applicant by the USPS, applicants should not file a duplicate, and should instead mail the original correspondence back to the USPTO as described in the notice "Suspension of the `Express Mail' Service of United States Postal Service for mail addressed to ZIP Codes 202xx through 205xx" that is posted on the USPTO Internet Web site at: http://www.uspto.gov/september11/uspsmaildisrup.htm.
Applicants who did not file an application using Express Mail may wish to consider filing a duplicate copy of the application via Express Mail, and not including the basic filing fee, or an authorization to charge the basic filing fee to a deposit account. When a duplicate application is submitted, applicant should anticipate that the duplicate (copy) application will be processed as a new application, any fees due will be attempted to be collected (as by either charging a deposit account if an authorization is given, or by mailing a Notice to File Missing Parts, requiring the filing fee(s)), and a filing receipt mailed. If the filing date accorded to the duplicate copy is an earlier filing date than that accorded the application that was previously mailed by first class mail, then applicant should respond to the Notice to File Missing Parts and pay the basic filing fee. If the application that was previously mailed by first class mail is given a filing date before that of the duplicate, applicant need not reply to the Notice to File Missing Parts in the duplicate application, and can just prosecute the original application (thereby allowing the later-filed duplicate application to go abandoned).

When applicant mails a reply to a Notice from OIPE using a certificate of mailing, the reply will be considered to be timely so long as the certificate of mailing was dated before the due date set in the Notice, regardless of the length of time that it took to reach the

USPTO. If the date of receipt of the correspondence was important, and applicant did not use Express Mail, and the response has not yet been received, applicant may wish to file a duplicate copy of the reply by Express Mail. An example of such a situation would be where a reply to a Notice of Omitted Items included a copy of a missing page of specification and requested a filing date of the date of receipt of the page of specification. The duplicate correspondence mailed to the Office pursuant to the Express Mail provisions of 37 CFR 1.10 will be given a filing date of the "date in" accorded by the USPS. If the duplicate is faxed to OIPE, the correspondence will be given a filing date as of the date of receipt, or if the actual date of receipt is a Saturday, Sunday or Federal Holiday, the next business day (see 37 CFR 1.6(a)(3)).

At the present time applications held in OIPE that are awaiting replies will not be processed as abandoned (if a reply could have been timely made during this period of delayed mail) and, therefore, calls requesting applicants to submit duplicate copies of replies to such notices will not generally be made. Calls to request such papers may be made for design applications.

VIII. Patent Term Adjustment:

Applications filed on or after May 29, 2000 may be eligible for patent term adjustment if issue of the patent has been delayed due to the failure of the Office to meet one of the time periods set forth in 35 U.S.C. 154(b)(1). See 35 U.S.C. 154(b). 37 CFR 1.703(f) provides that the date indicated on any certificate of mailing or transmission under 37 CFR 1.8 is not taken into account in a patent term adjustment calculation. If a reply to any Office action or notice is filed more than three months after the mailing date of the Office action or notice, the period between the date that is three months after the mailing date of the Office action or notice and the date of receipt (37 CFR 1.6) of the reply is considered a failure to engage in reasonable efforts to conclude prosecution, and any patent term adjustment to which the applicant would otherwise be entitled is required to be reduced by this period. See 35 U.S.C. 154(b)(2)(C)(ii) and 37 CFR 1.704(b). 35 U.S.C. 154(b)(3)(C) and 37 CFR 1.705(c), however, provide that an applicant may request reinstatement of all or part of the period of adjustment reduced pursuant to 35 U.S.C. 154(b)(2)(C) and 37 CFR 1.704(b) for failing to reply to an Office action or notice within three months of the date of mailing of the Office action or notice if the applicant provides a showing that, in spite of all due care, the applicant was unable to reply to the Office action or notice within three months of the date of mailing of the Office action or notice, but 35 U.S.C. 154(b)(3)(C) does not permit the Office to grant any request for reinstatement for more than three additional months for each reply beyond three months from the date of mailing of the Office action or notice.

If a reply to an Office action or notice was mailed on or after October 13, 2001 and no later than December 1, 2001 (as shown on a certificate of mailing under 37 CFR 1.8), and the applicant is

otherwise entitled to patent term adjustment (or additional patent term
adjustment) but for the fact that there was a reduction of such patent
term adjustment under 35 U.S.C. 154(b)(2)(C)(ii) and 37 CFR 1.704(b)
due to the receipt of such reply by the Office more than three business
days after the date indicated on the certificate of mailing, the Office
will consider the USPS mail situation discussed in this notice to
constitute a sufficient showing that, in spite of all due care, the
applicant was unable to reply to the Office action or notice within
three months of the date of mailing of the Office action or notice. In
this situation, the Office will, subject to the conditions set forth
below, reinstate a period equal to the period beginning on the date
that is four business days after the date indicated on the certificate
of mailing on the reply and the date of receipt (37 CFR 1.6) of the
reply in the Office up to a maximum of three months.

If an applicant's request for reinstatement of patent term
adjustment for the reason set forth above is the sole basis for
requesting a change to the patent term adjustment indicated on the
notice of allowance, the Office will waive the requirements of 37 CFR
1.705 (including fees) if the applicant submits a request for
reinstatement of patent term meeting the following conditions:

(1) The request is submitted no later than the payment of the issue
fee but no earlier than the date of mailing of the notice of allowance
(unless the paper that was delayed in the mail was the issue fee payment or
other paper submitted with or after payment of the issue fee, in which case
the request must be submitted as soon as possible but no later than the day
before the date of issue of the patent).

(2) The request is transmitted by facsimile to the Office of Petitions
at (703)308-6916.

(3) The request includes:
     (a) a copy of the part of page with the certificate of mailing
under 37 CFR 1.8 and a description of the paper (e.g., amendment, issue
fee transmittal, notice of appeal);
     (b) the date of receipt in the Office of the paper; and (c) the
number of days requested to be reinstated as a result of the USPS mail
situation discussed in this notice.

In addition, if applicant has access to the Patent Application
Information Retrieval (PAIR) system, a copy of the PAIR contents
records with the entry highlighted should also be included.

Applicants are again reminded that to maximize patent term
adjustment they may wish to consider filing replies to Office actions:
(1) under the "Express Mail" provisions of 37 CFR 1.10; (2) by facsimile;
or (3) by hand-delivery. See Changes to Implement Patent Term Adjustment
Under Twenty-Year Patent Term, 65 Fed. Reg. 56366, 56376 (Sept. 18, 2000),
1239 Off. Gaz. Pat. Office 14, 22-23 (Oct. 3, 2000) (final rule) (response
to comment 10).

IX. Contact Information:

http://www.uspto.gov/web/offices/com/sol/og/2002/week03/patdups.htm   2/7/200?

Duplicates in View of USPS Mail Delays - OG Date: 15 January 2002   Page 8 of 8

If you have a question relating to the status of a reply for an
application in a Technology Center, please contact the Customer Service
Representative of that Technology Center. If you have a question
relating to the receipt of a new application or a reply for an
application in OIPE, please contact the Customer Service Center in OIPE
at (703) 308-1202. If you have a question relating to the receipt of
post allowance correspondence, including issue and publication fee
payments, please contact the Customer Service Center of the Office of
Publications at (703) 305- 8283.

Questions concerning this notice should be directed to Darnell Jayne,
Legal Advisor, Office of Patent Legal Administration at (703) 308-6906.

December 20, 2001   ROBERT SPAR for
                                                        STEPHEN G. KUNIN
                                                     Deputy Commissioner for
                                                    Patent Examination Policy

EXHIBIT 17

UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

Dear Patent Practitioner,

The USPTO and the patent community have experienced considerable difficulties since mid-October 2001 due to delays in the delivery of mail by the US Postal Service. I want to assure you that the USPTO is making every effort to deal with this situation in ways that avoid any undue burden upon applicants. Over the last few weeks we have seen an increase in the volume of backlogged mail being delivered and we are working very hard to process this mail as quickly as possible. I ask that you bear with us during this challenge and work with us to the extent possible to minimize the impact of these mail delays.

Unfortunately the decontamination process has damaged some of the mail recently delivered to the USPTO. For example, some patent application papers and drawings including photographs have been stuck together and cannot be separated. Some computer discs have been damaged. Some labels have been blackened so that the text on them cannot be read and some papers have been yellowed and are brittle. The amount of damaged mail is small, about 5%, and the senders are being contacted to supply a duplicate when necessary. Additionally, no application is being held abandoned without us first calling the applicant to ensure that a reply has not been delayed in the mail.

I also understand that there has also been some concern from practitioners that outgoing mail from the Office may have been delayed in some instances. Currently, the USPTO is requesting that applicants follow the procedure set forth in Manual of Patent Examining Procedure (MPEP) 710.06 to establish a delay in receipt of mail if they want to request that the period for reply be reset.

Please consult the USPTO Internet web site (http://www.uspto.gov) for updated information on Technology Center facsimile numbers, surface mail alternatives, and other announcements concerning mail delays. Some notices related to the mail delays that have been recently posted on the USPTO web site are listed on the attached table. Section 511 of the MPEP will be revised to state that in the event of a postal emergency an announcement will be placed on the USPTO web site. Note also that the entry of a paper into an application file can be confirmed by checking the PAIR system via our Electronic Business Center on our web site.

Questions related to mail difficulties should be directed to the Office of Patent Legal Administration, by telephone at (703) 308-6906. Alternatively, the questions may be sent via e-mail to PatentPractice@uspto.gov.

Thank you for your continued cooperation as we deal with this difficult situation.

January 16, 2002
Date

/s/
NICHOLAS P. GODICI
Commissioner for Patents

Enclosure: Table of Recent Notices